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Summary
STATINS ARE among the most prescribed drugs in Western countries. They reduce
morbidity and mortality from coronary heart disease and mitigate the risk of stroke.
Their major site of action is the liver, where they inhibit HMG-CoA (hydroxyl-methyl-
glutaryl-coenzyme A) reductase, the rate-limiting step in cholesterol biosynthesis.
Inhibition of this pathway also inhibits various other processes, such as ubiquinone
production and the isoprenylation and N-linked glycosylation of proteins. Altering
these processes can reduce inflammation, oxidative stress and platelet adhesion –
leading to the positive effects of statins. However, inhibition of these processes can also
lead to negative side-effects, such as skeletal muscle myopathy, which is seen in 1–5% of
patients. These side-effects can impact on quality of life and compliance, and in extreme
cases lead to death. Uncovering the mechanism by which statins lead to these side-
effects is therefore of great urgency.
This thesis includes three papers that have been published or submitted for publication.
Our first paper presents a comprehensive comparison of the effects of simvastatin on
the cholesterol pathway and its intermediates in mouse skeletal muscle C2C12
myotubes and human liver HepG2 cells. C2C12 myotubes are susceptible to statin-
induced toxicity, whereas HepG2 cells are not. Differences between the two could
therefore point to possible toxic or protective mechanisms. We show that differences in
ubiquinone and cholesterol content are not responsible for toxicity, and suggest that
altered geranylgeranylation could cause toxicity in the C2C12 myotubes. We also show
a decrease in the rate of N-linked glycosylation in the C2C12 myotubes. This, and the
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need for geranylgeranylated proteins, suggests that an impairment in cell signalling
pathways is responsible for statin-induced toxicity.
Our second paper expands on these results by showing that an impairment in Igf-1/Akt
signalling leads to both mitochondrial toxicity and upregulation of the pro-atrophy
atrogin-1. We show that Igf-1/Akt signalling is not impaired in the HepG2 cells, and
that inhibition of this pathway makes the HepG2 cells sensitive to simvastatin. Finally,
we provide evidence that a small GTPase, Rap1, is integral to C2C12 myotube
mitochondrial integrity, and that mitochondrial respiration can be partially rescued by
expressing constitutively active Rap1 in those cells. Rap1 is a geranylgeranylated
protein that has been hypothesized to link cAMP/EPAC signalling to Igf-1/Akt
signalling, and is therefore a prime candidate as a causative factor in statin-induced
myotoxicity.
The final paper takes the work of the previous two papers and places it into a novel
environment – cardiac muscle. Statins are primarily prescribed to prevent
cardiovascular disease, and we present evidence that suggest that simvastatin can be
toxic in cardiomyocytes. We start with an observation of a lighter heart in simvastatin-
treated Wistar rats, and use ex vivo cardiomyocytes and in vitro H9C2 cardiomyocytes to
confirm toxicity. We show that, similar to the C2C12 myotubes, simvastatin leads to
mitochondrial dysfunction, inhibition of Igf-1/Akt signalling and upregulation of
atrogin-1 expression. This is the first time that these effects have been seen in the heart,
and warrant further investigation to ensure that these effects so not pose a risk in
susceptible patients
Page 3
Introduction
2.1. Cholesterol
CHOLESTEROL IS essential throughout the living world. It is used as a precursor to
steroid hormones, vitamins and bile acids.1-3 It is also an integral component of
membranes, where it ensures correct structure and stability.3 In animals, it is
synthesized in the liver, with extra cholesterol consumed in the diet. Excess cholesterol
is stored as cholesterylesters in cells.4 Circulating cholesterol is present in the plasma as
protein-lipid conjugates of varying densities, including: high density (HDL cholesterol);
low density (LDL cholesterol); and very low density (vLDL cholesterol).5 The
importance of cholesterol is seen in the inherited disorder, hypobetalipoproteinaemia.
In this disorder, circulating LDL cholesterol is reduced, and patients are susceptible to
neurological problems, sensory disorders and blood clotting.6 Conversely, high
cholesterol levels are also pathological, with high circulating LDL cholesterol being a
risk factor for atherosclerosis, cardiovascular disease, diabetes and stroke to name but a
few.7–11 The synthesis and regulation of cholesterol content is therefore vital for correct
cell and body function.
2.1.1. Why study cholesterol?
Cardiovascular disease is the number one killer of adults in the Western world.12–14 A
combination of bad diet and little exercise, amongst other factors, leads to build-up of
cholesterol-rich LDL-cholesterol in atherosclerotic plaques, and presentation of the
disease. Considering the increasing number of elderly and obese people in Western
populations, understanding and controlling how cholesterol is produced is of
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paramount concern. There is a need for better prevention of cardiovascular and related
diseases, in order to save both lives and money, and increase quality of life in affected
individuals. Cholesterol-lowering is the main preventative measure, and understanding
the cholesterol pathway and how it can be inhibited has therefore been of great
importance.15
2.1.2. Cholesterol synthesis: The mevalonate pathway
Endogenous cholesterol is produced in the cytoplasm and endoplasmic reticulum (ER)
of liver cells via the mevalonate pathway (Fig 1). Acetyl-CoA is converted to 3-hydroxy-
3-methyl-glutaryl-CoA (HMG-CoA) via HMG-CoA synthase. The conversion of HMG-
CoA to mevalonate is the rate-limiting step, and is performed by HMG-CoA reductase
(HMGCR). From here, isopentenyl pyrophosphate (IPP) is formed and converted to
geranylpyrophosphate (GPP) and farnesylpyrophosphate (FPP). FPP is converted to
squalene, which leads through to cholesterol.16
Figure 1
The mevalonate pathway. Cholesterol production from acetyl CoA, with the later
stages in bold. The bold intermediates are important in other processes such as
isoprenylation and N‐linked glycosylation. ① HMG‐CoA synthase  ② HMG‐CoA
reductase  ③ Mevalonate kinase & phosphomevalonate kinase  ④ Mevalonate‐
5‐pyrophosphate  decarboxylase  ⑤  Farnesyl‐PP  synthase  ⑥  Geranyl‐PP
synthase  ⑦ Squalene synthase
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2.1.2.1. Regulation of cholesterol metabolism
The pioneering work of Goldstein and Brown in the 1970s began to unravel the complex
regulation of cholesterol metabolism. They first observed that familial
hypercholesterolemia was associated with a lack of LDL receptors, and then vastly
expanded upon this. They discovered a feedback loop linking external cholesterol and
the number of LDL receptors, and also a feedback loop linking cholesterol uptake and
cholesterol production.17 All this work came to a climax in 1993, when Yokayama,
supported by Goldstein and Brown, discovered the sterol regulatory element binding
proteins (SREBPs).18 These transcription factors are controlled by the amount of
cholesterol in the cell (Fig 2). High cholesterol concentrations keep the SREBPs in an
inactive state, whereas low cholesterol concentrations lead to their cleavage from
inhibitory factors, activation and translocation to the nucleus. At the nucleus, they bind
to sterol regulatory element DNA sequences, and upregulate transcription of genes
associated with cholesterol synthesis or uptake (such as those for HMGCR and the LDL
receptor).18,19
Figure 2
Regulation of SREBPS. These are
kept in an inactive state in the
presence of high cholesterol. Low
cholesterol levels release SREBP from
the inhibitory complexes, and lead to
cleavage to the active transcription
factor. SREBPs transcribe many
genes, including those important for
cholesterol production and uptake.
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2.1.2.2. Regulation of HMGCR
HMGCR is one of the most highly regulated enzymes in the human body. HMGCR
transcription is enhanced by SREBP binding, but the importance of the mevalonate
pathway demands multiple levels of regulation.20 Recently, alternative splice forms of
HMGCR have been discovered.21 Although not completely characterized, one splice
variant (HMGCR-D13) lacks part of the catalytic domain that is important for binding
the substrates. A functional SNP (rs3846662) that regulates the splicing of HMGCR has
also been recently discovered.22 Phosphorylation of HMGCR by an AMP-activated
protein kinase leads to a reversible inhibition of the enzyme.20 This inhibition ensures
that acetyl-CoA is not used to produce cholesterol during times of low cellular energy
(when AMP would be high, and induce HMGCR phosphorylation). A similar
phosphorylation inactivates acetyl-CoA carboxylase, the rate-limiting enzyme in fatty
acid metabolism, providing further control of acetyl-CoA levels during low energy
status.20
2.2. Statins
At the same time as Goldstein and Brown were working on regulation of the
mevalonate pathway, Endo derived two compounds from the fungus Penicillium
citrinum that could competitively inhibit HMG-CoA reductase.23,24 He named one of
these compounds mevastatin, and Goldstein and Brown used this compound to inhibit
HMG-CoA reductase in fibroblasts from hypercholesterolemia patients.25 Endo then
used a rat model to demonstrate in vivo the ability of mevastatin to reduce cholesterol
synthesis. This work also shows that the inhibition is mostly found in hepatic HMG-
CoA reductase, where most cholesterol is produced.26
The isolation of lovastatin by Merck heralded a new era in the treatment of
cardiovascular disease.27,28 Following extensive clinical trials, lovastatin received FDA
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approval in 1987.29 Evidence followed linking statin use with a reduction of mortality in
people with high cholesterol.30–32 Since that time, further statins have been derived and
synthesized, including simvastatin, atorvastatin, pitavastatin and cerivastatin (Fig 3).33,34
2.2.1. Side-effects of statins
Statin use has been increasing since their release onto the market, a trend that is likely to
continue as elderly and obese populations grow. Potential side-effects must therefore be
understood and prevented. The most severe side-effect is rhabdomyolysis, which is
characterized by destruction of skeletal muscle leading to the release of muscle proteins
and compounds into the blood.35–38 Release of potassium can lead to disruption in heart
rhythm, and phosphates can cause hyocalcemia by precipitating with calcium in the
blood.39 The most severe consequence of rhabdomyolysis is the accumulation of
myoglobin in kidney tubules, which can severely damage the kidney via acute tubular
necrosis and eventually lead to kidney failure if left untreated. Rhabdomyolysis is
usually associated with a sharp increase in serum creatine kinase (CK) levels to over 10
Figure 3
Structure of simvastatin. The three
main structural regions of statins:
(red) the pharmacophore, which is
structurally similar to HMG-CoA;
(yellow) a butyryl group for type 1
statins, or a flurophenyl group of
type 2 statins; (blue) decalin ring
structure of type 1 statins, type 2
statins have larger groups.
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times normal levels. Statin toxicity became of public interest in 2001, when cerivastatin
was withdrawn from the market.40,41 Fifty-two deaths from rhabdomyolysis were
caused by the drug.42 The risk of rhabdomyolysis was 10 times higher than with other
statins, and those on combination therapy with gemfibrozil were at particular risk.43,44
Health organizations were prompted to reassure statin users of the safety and benefits
of the taking the remaining statins. Rhabdomyolysis now occurs at a rate of 0.44 per
10,000 patient years.38
Although extreme, rhabdomyolysis is not the only side-effect associated with statin-use.
Other myopathies occur in 1–5% of patients, and myalgias in 9–20%.35–38,45–47 Less serious
skeletal muscle effects may be even more frequent, and may lead to a reduced quality of
life and lack of treatment compliance.
2.2.1.1. Risk factors
Side-effects are usually dose-dependent, with Silva et al. showing a 10-fold increase in
myopathy in patients taking a high dose of atorvastatin or simvastatin (80 mg/day)
compared to patients on a lower dose.48 The positive side to the high dose is a
decreased risk of cardiovascular disease.49
Myotoxicity is associated with all statins, but to varying degrees.38,50 A large variation in
the pharmacokinetic properties of the different statins could be a factor in determining
which statins lead to more side-effects.50 Lipophilicity also varies between the statins
(for example, simvastatin is lipophilic whereas pravastatin is not, meaning simvastatin
can enter a cell more easily than pravastatin).50
Interactions with other drugs, as highlighted with cerivastatin and gemfibrozil, are also
risk factors for skeletal muscle side-effects. Three commonly prescribed statins –
simvastatin, lovastatin and atorvastatin – are metabolized by CYP3A4.51–53 This
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isoenzyme metabolizes more than 50% of prescribed drugs, leading to a large risk of
drug-drug interactions.54,55 Co-treatment with inhibitors of CYP3A4 could also raise
concentrations of statins, and therefore increase the risk of side-effects.56,57 One study
suggests that simvastatin-associated muscle disorders were six-fold higher when
patients were taking CYP3A4 inhibitors at the same time.58 They saw no change in
patients taking CYP3A4 inhibitors with pravastatin (which is not metabolized by
CYP3A4).58 Fluvastatin is primarily metabolized by CYP2C9, and is therefore subject to
possible interactions with CYP2C9 inhibitors, such as diclofenac and fluconazole.59,60
In addition to drug metabolism, drug uptake also has an effect on the risk of skeletal
muscle side-effects.61 The hepatic transporter OATP1B1 is the main transporter of
statins into the liver (Fig 4). Inhibiting uptake may lead to increased plasma statin levels,
which may be how gemfibrozil increases risk of myopathy.61 The gene encoding
OATP1B1, SLCO1B1, is also the only gene which has been associated with risk for
statin-induced myopathy.62 A genome-wide study in patients who suffered statin-
induced myopathy identified only one associated polymorphism – over 60% carried the
rs4363657 SNP in SLCO1B1.62
Figure 4
Statin metabolism in the liver.
Statins enter liver cells via SLCO
transporters (rectangle in baso-
lateral membrane). Some statins
are metabolized by CYP450
enzymes (green circles). Statins
and their metabolites are then
excreted at the apical membrane
via ABC trans-porters (rectangle in
apical mem-brane). The isoforms
of all these enzymes vary from
statin to statin.
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There are also reports of statins exacerbating or
uncovering muscle conditions such as
myasthenia gravis, McArdle’s disease and
myotonic dystrophy.63–65 These studies suggest that care should be taken when
prescribing statins to patients with signs, or a family history of, muscle disorders.
2.3. Linking the mevalonate pathway to statin-induced myopathy
The mechanisms of statin-induced myopathy are not fully elucidated. The fact that the
mevalonate pathway not only produces cholesterol, but a myriad of other essential
compounds, enables statins to affect many cellular processes – any or all of which might
contribute to myopathy.
2.3.1. Cholesterol
Cholesterol is produced via the mevalonate pathway (Fig 5). Previous in vitro studies in
rat skeletal muscle show that squalene, the direct precursor to cholesterol, cannot rescue
statin-induced myotoxicity.66 Inhibitors of squalene synthase do not cause muscle
toxicity either.67 This is strong evidence that it is not cholesterol-lowering that leads to
toxicity. Further evidence is provided by our studies showing that simvastatin is toxic
to C2C12 myotubes even when cellular cholesterol levels are not decreased.68
Figure 5
Structure of cholesterol. The three main
regions are shown: (red) a polar hydroxyl
group; (blue) four hydrocarbon rings, which
forms the basis of all steroid hormones;
(green) a non-polar hydrocarbon ring.
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2.3.2. Ubiquinone
Ubiquinines are also produced via the
mevalonate pathway (Fig 6). Ubiquinones
are used as electron carriers between
complex I or II and complex III in the
mitochondrial electron transport chain
(ETC).69 It is hypothesized that disruption
of ubiquinone production may lead to
dysfunction of the electron transport
chain, which could reduce muscle cell
ATP levels, increase radical production
and lead to apoptosis.70,71 Further to this, ubiquinone is also an important antioxidant in
its reduced form.72 Ubiquinones are also involved in regulating the mitochondrial
permeability transition pore.73 Depletion of ubiquinone plays a role in some
mitochondrial myopathic diseases, although its role in statin-induced myopathy is more
controversial. Numerous in vitro studies show no reduction in ubiquinone levels after
statin treatment.68,74,75 Studies in humans also show ubiquinone supplementation does
not reverse myopathy during statin treatment.76,77 Despite this, numerous clinicians
suggest ubiquinone supplements to patients on statin treatment.
2.3.3. N-linked glycosylation
N-linked glycosylation requires dolichol, a polyprenol downstream from farnesyl- and
isopentyl-pyrophosphate (Fig 7). Oligosaccharides need to be linked to dolichol before
they are added to asparagine residues of target proteins, and dolichol is then cleaved
during the linkage to asparagine.78 N-linked glycosylation is required for the correct
function of many proteins. It increases protein stability and facilitates
Figure 6
Structure of ubiquinone. Ubiquinones have two
region: (purple) the quinine structue; (red) the
isoprenoid side-chain, the number of which varies
depending on the ubiquinone, here it represents
CoQ10.
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interactions between proteins and ligands.79 An example is the Igf-1 receptor (Igf-1r).
This receptor requires correct N-linked glycosylation before it can be cleaved from the
proreceptor to the mature receptor.80–82 Statins are known to increase levels of the
proreceptor, decrease expression of the mature Igf-1r at the cell surface and promote
apoptosis in Ewing’s sarcoma, and other, cells.80,82,83 Insufficient N-linked glycosylation
may also contribute to congenital muscular dystrophies, suggesting that statin-induced
disruption of N-linked glycosylation in muscle could present as a myopathy.84
2.3.4. O-mannosylation
Dolichol is also required for the addition of O-mannosyl groups to proteins.85,86 Proteins
that are O-mannosylated are important in muscle and brain development, and are
therefore candidates for causative factors in statin-induced myopathy.87 One protein
that is O‑mannosylated is α‑dystroglycan (α‑DG), one of many proteins that form the
dystrophin-glyoprotein complex in skeletal muscle.88 The dystrophin-glycoprotein
complex acts as a transmembrane bridge between the intracellular cytoskeleton and
extracellular matrix; disruption of this complex could therefore have a negative effect
on the structure of skeletal muscle fibres (Fig 8).88–90 Walker-Warburg syndrome, a
congenital disorder, shows the importance of correct O-mannosylation.91–93 This
Figure 7
Importance of dolichol in N-linked
glycosylation. The process is shown
at the ER, with dolichol phosphate
anchoring oligosaccharide chain
(red) composed of N-acetylgluco-
samine (yellow) mannose (blue), and
glucose (purple) to the ER mem-
brane. The oligosaccharides are
transferred to an asparagine residue
on the translated protein, with
dolichol phosphate remaining in the
ER membrane.
Continued on page 14
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Figure 8
Disruption of the dystrophin-
glycoprotein complex.
1. Normal  muscle.  α‐dystro‐
glygan is heavily O-manno-
sylated (yellow, red and blue
groups). O-mannosylation links
α‐dystroglycan  to  extracellular
matirix proteins (shown in
black). α and β dystroglycan can
then act as a link between the
intracellular cytoskeleton and
the extracellular matrix.
2. Walker-Warburg muscle. A
lack of O-mannosylation pre-
vents  the  link  between  α‐dyst‐
roglycan and the extracellular
matrix.
Figure 9
Incorporation of selenium into sec-tRNAsec. Naked tRNA incorporates a serine (green), which is
then phosphorylated (yellow) and replaced by a selenocysteine (red). SerRS: Seryl-tRNA
synthetase, PSTK: O-phosphoteryl-tRNA kinase, SepSecs: Sep-tRNA:Sec-tRNA synthase.
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disorder is caused by mutations in the
enzymes that link the O-mannosyl moiety
to proteins, and leads to congenital
muscular dystrophy. A statin-induced
lowering of dolichol levels in skeletal
muscle could therefore lead to a
breakdown in muscle structure.
2.3.5. Selenocysteine tRNA
Isopentyl pyrophosphate is required for the correct production of selenocysteine tRNA.
It is added to an adenosine, without which there is an 80–90% reduction in
selenoprotein translation (Fig 9).94 Selenocysteine tRNA is required for the production
of selenoproteins, a small group of proteins that have not been greatly studied yet.95,96
Selenoproteins are important in numerous cellular functions, one being the antioxidant
glutathione pathways that provide protection from reactive oxygen species.97 Selenium
deficiency is known to cause numerous skeletal muscle disorders, including myotonic
dystrophy, multiminicore disease and white muscle disease.98–100 Multiminicore disease
can be caused by mutations in the selenoprotein N gene, SelN, leading to a loss of
organization of muscle fibres.101 Selenoproteins are also important in maintaining
correct cardiac muscle function, and low dietary selenium is associated with two
cardiomyopathies: Keshan disease and Chagas’ disease.102,103
A statin-induced reduction of isopentyl pyrophosphate has been shown to lead to a
reduction in selenoprotein translation, which could therefore impact both skeletal and
cardiac muscle function.94
Continued from page 12
Figure 10
Structure of geranylgeranylpyrophosphate. There are two
main regions: an isoprenoid region (yellow) containing 20
carbons, (note that farnesylpyrophosphate contains only
15 carbons) a pyrophosphate group (purple).
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2.3.6. Prenylation
Prenylation involves the addition of a farnesyl or geranylgeranyl moiety to a protein at
a C-terminus cysteine. Farnesyl and geranylgeranyl moieties are derived from
intermediates of the mevalonate pathway (Fig 10).104 They are added to numerous
proteins, but particularly small GTPases, and contribute to correct localization.105,106
Small GTPases play myriad critical roles in multiple signalling pathways controlling
cell growth, repair, differentiation and adhesion.107–110 One small GTPase that is
farnesylated is Ras. Ras has received a lot of attention due to it being hyperactive in
many types of cancer.111 The importance of its farnesyl group in correct localization led
to much research into the use of farnesyltransferase inhibitors (FTIs) to prevent cancer
development.112–113 These studies met with mixed success, probably due to the ability of
Ras to compensate for loss of a farnesyl group by addition of a geranylgeranyl group.114
Figure 11
Mitochondrial electron transport chain and oxidative phosphorylation. The complexes are in the
inner mitochondrial membrane. Substrates can be reduced at complex I or complex II. The
electrons flow through the first four complexes, facilitating the efflux of protons into the
intermembrane space. A proton gradient is built, and protons flow back through complex V (ATP
synthase), with the energy released enabling the production of ATP.
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Geranylgeranylation is a promising area of research into the toxicity of statins.
Addition of geranylgeraniol (GGOH) to statin-treated cells rescues them from
apoptosis, and treating cells with geranylgeranyltransferase inhibitors (GTIs) increases
apoptosis, suggesting that geranylgeranylated proteins play a major role in statin-
induced myotoxicity.68,74,115 This is given further credence by a study by Itagaki et al.
showing that simvastatin-induced cell death in L6 myoblasts is accompanied by a
redistribution of the small GTPase RhoA from the plasma membrane to the
cytoplasm.116
2.4. Potential mechanisms of myopathy
2.4.1. Direct effects on the mitochondrial ETC
The mitochondria ETC is an essential energy-producing process in cells (Fig 11). Statins
have been shown to directly inhibit complexes of the mitochondrial ETC. One study
shows that complex IV of the ETC is impaired, whereas Nadanaciva et al. showed all
complexes except complex II in rat livers are inhibited by both simvastatin and
lovatstatin.117,118 The inhibition cannot be due to a change in prenylation or N-linked
glycosylation of the proteins involved, as the inhibition occurs both immediately and on
isolated mitochondria. A direct inhibition of the ETC would have drastic effects on the
cells, as energy levels would be depleted, mitochondrial integrity compromised, and
apoptosis triggered.119 It is worth pointing out that many studies of mitochondrial ETC
complex activities use very high concentrations of statins.118,120 Whether localized
concentrations of statins could reach high enough levels in the mitochondria of patients
is debatable, but the mitochondria may already be compromised in patients or genetic
variations in the complexes or transporters may make more people susceptible.121
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Further evidence of a direct effect of statins on the mitochondrial ETC is provided by
Sirvent et al.122 They present data showing that simvastatin induces an efflux of Ca2+
from the mitochondria of isolated human muscle fibres. They suggest that the efflux is
caused by a disruption in mitochondrial function, as a result of a direct inhibition of one
or more of the complexes of the ETC. Altered Ca2+ homeostasis in the muscles could
lead to muscle dysfunction and dysregulation.122
2.4.2. Effects on glycolysis
Cells can also produce energy via glycolysis (Fig 12). The glycolytic pathway converts
glucose into pyruvate with a net production of two ATP molecules and two NADH
molecules.123 Previous studies show that glycolysis can also be affected by statins.124,125
One possible mechanism is via direct or indirect inhibition of one of the enzymes
involved in the pathway by altering post-translational modifications or interfering in
Glycolysis. Two ATPs are used to convert one glucose to two glyceraldehyde-3-phosphates. The
splitting of the glucose is shown by an orange and green arrow after glycerahdehyde-3-
phosphate. The two glyceraldehyde-3-phosphates are converted to two pyruvates, with the
production  of  four  ATPs,  leaving  a  net  gain  of  two  ATPs.  ①  Glucokinase  /  hexokinase
② Phosphoglucoisomerase  ③ Phosphofructose kinase  ④ Aldolase  ⑤ Glyceraldehyde‐3‐
phosphate  dehydrogenase  ⑥  Phosphoglucokinase  ⑦  Phosphoclucomutase  ⑧  Enolase
⑨ Pyruvate kinase
Figure 12
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activation or regulation of
activity. A second
mechanism has been
postulated by Klawitter et al.
who show that lovastatin can
reduce the expression of
enzymes involved in
glycolysis (such as trio-
sephosphate isomerise 1, α‑
enolase and dihydrolipo-
amide S-acetyltransferase).125 A reduction in glycolysis could compromise the ability of
a cell to produce energy and, especially if combined with inhibition of mitochondrial
ETC, lead to apoptosis.
A statin-induced inhibition of glycolysis could also explain the beneficial effects of
statin treatment in some cancers. Cancer cells generally have an increase in ATP
production via glycolysis, so that they can counteract the anaerobic environment found
in the centre of tumour tissues (the Warburg effect).126 Numerous studies show that
cancer cells are sensitive to the inhibition of glycolysis, and that drugs that target this
process may form an effective strategy in overcoming the Warburg effect.127–129 This
could also overcome drug resistance, lead to cancer cell apoptosis and have a large
clinical impact in cancer care. Statins may form part of this strategy.
2.4.3. Atrogin-1: A prime candidate
2.4.3.1. Evidence of a role in statin-induced myopathy
Much work has focussed on linking upregulation of an atrophy-inducing protein,
atrogin-1, during statin-induced myopathy.115,130 Atrogin-1 is an E3 ubiquitin ligase,
E3-ligase action of atrogin-1. Atrogin-1 adds ubiquitin groups (blue)
to proteins, targeting them for degradation by the proteasome.
Figure 13
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which is involved in the ubiquitylation and degradation of proteins (Fig 13).131–133
Atrogin-1 is tightly regulated at the transcriptional level by the Foxo transcription
factors, Foxo1 and Foxo3a.133 Nuclear localization of the Foxo transcription factors is
determined, in part, by their phosphorylation state.134 Phosphorylated Foxo1 and
Foxo3a are excluded from the nucleus, and therefore unable to transcribe the atrogin-1
gene. Phosphorylation of Foxo1 and Foxo3a is controlled, in part, by signalling through
the Igf-1/Akt pathway.134 Igf-1 signalling leads to phosphorylated, active Akt, which
can then phosphorylate Foxo1 and Foxo3a. The integral role of the Igf-1/Akt pathway in
preventing atrophy is shown by Igf-1 treatment reducing transcription of atrogin-1, and
rescuing the cells from atrophy (Fig 14).135,136
Hanai et al. presented stunning evidence of the integral role atrogin-1 plays in statin-
induced myopathy. They found that atrogin-1 knockout mice and knockdown zebrafish
are resistant to statin-induced myopathy.130 Cao et al. add to this by showing that
Figure 14
Control of atrogin-1 transcription
by Igf-1/Akt/Foxo signalling. Sig-
nalling through the IGF-1 receptor
(yellow) leads to phosphorylated
Akt. Phosphorylated Akt can, in
turn, phosphorylate Foxo tran-
scription factors, leading to their
exclusion from the nucleus. Red-
uced Akt phosphorylation leads to
an increase in unphorsphorylated
Foxos, which can translocate to
the nucleus and transcribe
atrogin-1.
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addition of GGOH to statin-treated mice and zebrafish preventrs atrogin-1 expression
and statin-induced muscle damage.115
How statins can lead to a dysregulation of Igf-1/Akt signalling, and the corresponding
increase in atrogin-1 levels, is unknown. It could be that statins directly affect the Igf-1r.
As mentioned previously, the Igf-1r requires N-glycosylation for correct cleavage from
its proreceptor form to the mature, plasma membrane localized, receptor.80–83 A
decrease in mature Igf-1r could lead to reduced Akt phosphylation, increased nuclear
translocation of Foxo1 and Foxo3a, and an upregulation in atrogin-1 synthesis. A
second possibility is that statins alter the prenylation of various small GTPases such as
Ras, Rap1, Rac or Rho. Small GTPases are integral in many signalling pathways, and
their incorrect processing could also reduce Igf-1/Akt signalling.137–138
Postulated link between cAMP/Epac and Igf-1/Akt signalling. cAMP is produced after
signalling through G-protein coupled receptors. cAMP, binds to Epac, enabling the conversion
of inactive GDP-Rap1 to the active GTP-Rap1 (yellow). Rap1 might stimulate PI3K (red), an
integral component of Igf-1/Akt signalling.
Figure 15
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2.4.3.2. Rap1: Linking statins to atrogin-1?
Rap1 is a small GTPase that is involved in numerous cell processes, most notably cell
adhesion.139–141 As it is a small GTPase, it is regulated by guanine nuclear exchange
factors. One family of such exchange factors are the exchange proteins directly activated
by cAMP (EPACs). EPACs are activated by cAMP signalling, leading to an activation of
Rap1.142,143 Numerous studies link cAMP/EPAC/Rap1 signalling to Igf-1/Akt signalling,
although it is not completely known where the two pathways interact (Fig 15).44,146 Work
by Baviera et al. in extensor digitorum longus muscles from rats, points to Rap1
interacting with PI3K, downstream of the Igf-1r but upstream of Akt.147 Gonçalves et al.
linked cAMP signalling with atrophy in a paper in 2009.148 They showed that increasing
cAMP levels, via the cAMP phosphodiesterase inhibitor isobutylnethylxanthine (IBMX),
negated the increase in atrogin-1 expression induced by dexamethasone. This negation
was via an increase in Akt phosphorylation, and concomitant increase in Foxo
phosphorylation and nuclear exclusion.
The above work offers tantalizing evidence that statins could inhibit Igf-1r/Akt
signalling via inhibition of cAMP signalling through Rap1.
2.5. Can dysregulation of Igf-1/Akt signalling also explain the effects on
mitochondria?
Since cell energy status, survival and apoptosis are dependent upon the mitochondria,
it is important to integrate cell survival signalling and mitochondria. It is therefore of no
surprise to discover that mitochondria are also controlled by cellular signalling
pathways. Numerous studies report the influence of all the major cell signalling
pathways upon mitochondrial function, from PKA to ERK and JNK.149–151 Of particular
interest is the influence of Igf-1/Akt signalling upon the mitochondria, as this is the
pathway most associated with dysfunction in statin-induced myopathy.115
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Akt is known to inhibit the pro-apoptotic protein Bad (Fig 16). Active Akt directly
phosphorylates Bad, which causes Bad to dissociate from anti-apoptotic proteins, and
then bind to the adaptor protein 14-3-3.152–154 The anti-apoptotic proteins, such as
members of the Bcl-2 family, are then free from inhibition and cell survival is
encouraged. Akt is also able to phosphorylate Bax, inhibiting its ability to enhance
mitochondrial pore formation and prevent the release of cytochrome c.155–157
Akt can also regulate metabolism via regulating the activities of hexokinases (HKs) and
voltage dependent anion channels (VDACs) (Fig 17). HKs control the first step of
glycolysis, the conversion of glucose to glucose-6-phosphate.158 Two isoforms, HK I and
HKII, are also known to bind to the outer mitochondrial membrane, and become
dissociated from there during apoptosis.159 Overexpression of HKI or HKII can protect
cardiomyocytes from H2O2-induced cell death, and this protection is lowered when the
mitochondrial binding motifs are deleted.160 HKII has been particularly linked with
being a downstream effector by which Akt can inhibit cell death.161,162 The fact that both
Multiple roles of Akt at the mitochondria. Phosphorylated Akt can inhibit pro-apoptotic
proteins (red), and also prevent them sequestering anti-apoptotic proteins (green).
Figure 16
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Akt and HKs require glucose to promote cell survival suggests a link.157,163 Further
evidence is provided by human HKII containing an Akt consensus sequence important
in enabling Akt to phosphorylate its targets.164 Akt is able to phosphorylate HKs and
block their dissociation of HKs from the outer mitochondrial membrane, and therefore
prevent apoptosis.163 The importance of HK localization at the outer mitochondrial
membrane is highlighted by HK-dissociation impairing the anti-apoptotic effects of Akt,
and also its ability to promote mitochondrial integrity.165 Akt therefore acts as a
common mediator of cell survival and energy metabolism.
VDACs are important pores on the outer mitochondrial membrane, and are also
regulated by Akt signalling. They maintain the polarization of the outer mitochondrial
membrane.166–168 When unphorsphorylated, VDACs bind to HKs, the VDAC pore is
kept open and HKs have access to mitochondrial ATP.166–168 Dissociation is caused by
phosphorylation by GSK3β.169  Active GSK3β is known to promote apoptosis, and
GSK3β is inactivated by Akt.170–172 Akt can therefore enhance HK binding to VDAC by
both phosphorylation of HKs and preventing the phosphorylation of VDACs.
Figure 17
The importance of Akt in
maintaining HK/VDAC inter-
actions. Phosphorylated Akt
phosphorylates hexokinase II,
enabling its localization to the
outer mitochondrial membrane.
Phosphorylated Akt also inhibits
GSK3β  via  phosphorylation,  pre‐
venting it from phosphorylating
VDAC. This keeps the VDAC-
hexokinase II complex together.
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It is therefore clear that Igf-1/Akt signalling is integral to mitochondrial stability, energy
metabolism and prevention of cell death. The fact that statins are known to disrupt Igf-
1/Akt signalling offers a potential explanation as to how they can inhibit mitochondrial
function as well.
2.6. Linking atrogin-1 to the mitochondria
Atrophic muscle fibres also have disruptions in their mitochondria, and stimulation of
mitochondria biogenesis by overexpression of PGC1α can inhibit muscle atrophy.173 A
recent study by Romanello et al. highlights the important role the mitochondria network
plays in muscle atrophy.174 They present evidence that mitochondrial fission is an
integral part of atrophy, and that preventing fission also prevents atrophy. They
suggest that mitochondrial fission enhances the activation of Foxo3a independent of its
phosphorylation state, probably via AMPK signalling. The activated Foxo3a is then able
to translocate to the nucleus and enhance transcription of pro-atrophic genes such as
atrogin-1. Whether mitochondrial fission and fusion are affected by statins are
unknown, but other drugs such as berberine are known to affect both mitochondrial
function and upregulate atrogin-1 expression.175
2.7. Statins and cardiac muscle
Statins are mainly taken to combat cardiovascular disease, yet side-effects of statins in
cardiac muscle have been much less studied than in skeletal muscle. There are only a
few papers on the subject, which show that lovastatin can reduce cardiomyocyte
viability, in part via an increase in apoptotic pathways.176,177 This suggests an effect of
statins on cardiac mitochondria. Atrogin-1 is also present in cardiac muscle, and is
known to be upregulated during experimental heart failure.178,179 It is therefore possible
that statins could induce increase in atrogin-1 expression in the heart as they do in
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skeletal muscle. These side-effects may be missed by falsely attributing them to the
underlying cardiovascular disease
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Aims
THIS THESIS has three main aims. Firstly, we aimed to uncover differences between the
effects of simvastatin on skeletal muscle and liver. As simvastatin is not toxic in liver,
we reasoned that determining these differences would point to possible mechanisms for
simvastatin-induced skeletal muscle toxicity. We chose the well-established skeletal
muscle cell line C2C12, and induced differentiation to myotubes, to represent skeletal
muscle. Simvastatin does not induce toxicity in the human liver HepG2 cell line, and
hence we chose that to represent the liver.
We initially performed a comprehensive analysis of the different components of the
cholesterol synthesis pathway, and looked for differences in these components. This
was be the first time such an analysis would have been performed, and would offer
suggestions into how simvastatin leads to skeletal muscle toxicity.
The second aim of this thesis was to expand these differences by investigating effects on
the mitochondria and the Igf-1/Akt signalling pathway in C2C12 myotubes and HepG2
cells. Statins have been reported to inhibit mitochondrial function in various cell lines,
and we aimed to uncover why simvastatin is only inhibitory in the C2C12 myotubes
and not the HepG2 cells. As mitochondrial integrity and function are controlled by
various signalling cascades, we looked for differences in the Igf-1/Akt pathway – a
pathway implicated in statin-induced toxicity.
The final aim of this thesis was to look for toxicity in cardiac muscle. This has not been
investigated before, but is of great importance as preventing cardiovascular disease is a
major reason for prescribing statins. We used our results from our C2C12 myotube
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studies as a guide, and investigated how simvastatin affects cardiac mitochondria and
atrophic pathways. We used in vivo, ex vivo and in vitro techniques to present, for the
first time, evidence of a toxic effect of simvastatin in cardiomyocytes
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Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2
cells, and consequences for statin-induced myopathy
Peter James Mullen a,*, Barbara Lu¨scher a, Hubert Scharnagl b, Stephan Kra¨henbu¨hl a, Karin Brecht a
aDivision of Clinical Pharmacology & Toxicology, Department of Research, University Hospital Basel, Hebelstrasse 20, CH-4031 Basel, Switzerland
bDepartment of Clinical Chemistry, University of Graz, Graz, Austria
1. Introduction
Statins, hydroxyl-methyl-glutaryl-coenzyme A reductase
(HMG-CoA) inhibitors, are among the most prescribed drugs in
Western countries. They reduce morbidity and mortality from
coronary heart disease and mitigate the risk of stroke [1,2]. Their
major site of action is the liver. Statins inhibit HMG-CoA reductase,
the rate-limiting step in cholesterol biosynthesis. This reduces
hepatic cholesterol production, leading to increased LDL receptor
expression, enhanced uptake of circulating LDL particles, and a
reduction in peripheral LDL levels [3,4]. They are generally well-
tolerated but there are dose-dependent side effects, particularly in
skeletal muscle. Myopathy occurs in 1–5% of patients, and can lead
to fatal rhabdomyolysis if not recognized [5–8]. Themechanisms of
statin-induced myopathy are not fully elucidated.
Statins are thought likely to induce myopathy by disrupting
isoprenoid intermediates in the cholesterol synthesis pathway [9].
Ubiquinones, for instance, are produced from the isoprenoid
geranylgeranyl pyrophosphate [10]. A reduction in geranylgeranyl
pyrophosphate production under statin therapy has been impli-
cated in the reduction of the production of ubiquinones, which are
used as electron carriers in the electron transport chain [6,11].
Therefore, disruption of ubiquinone production may lead to
dysfunction of the electron transport chain, which could reduce
muscle cell ATP levels, increase radical production and lead to
apoptosis [6,11].
The post-translational modifications of isoprenylation and N-
linked glycosylation are also dependent on the cholesterol
synthesis pathway. Many small GTPases, such as Ras and Rap1,
are isoprenylated via the addition of farnesyl or geranylgeranyl
moieties. Altered isoprenylation affects the localization and
activity of such proteins. This may alter normal cell growth and
differentiation as they are involved in the control of the cell cycle
and entry into apoptosis [12–14]. The isoprenoid dolichol is
required in N-linked glycosylation to link sugars to proteins [15].
Many proteins, such as a-dystroglycan and the IGF-1 receptor,
require correct N-linked glycosylation [16,17]. N-glycosylated
proteins have various roles within cells: the IGF-1 receptor is
important in regulating cell growth and differentiation, while a-
dystroglycan forms part of a complex that links the cytoskeleton to
the extracellular matrix. Disrupting these processes leads to cell
death, and skeletal muscle damage [18,19].
Previouswork shows how statins affect cholesterol metabolism
in liver cells [20,21]. No studies have so far investigated the effect
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of statins on cholesterol metabolism in skeletal muscle cells. To
address this, we used mouse C2C12 myotubes to model skeletal
muscle. C2C12 myotubes are a well-established in vitro model for
skeletal muscle studies. This is the first study to characterize the
effects of statins on skeletal muscle cholesterol metabolism in
vitro. For comparison we used HepG2 cells to model the hepatic
system, as they are a well-characterized hepatic model. This
allowed us to elucidate differences between the effects of
simvastatin on liver and skeletal muscle cholesterol metabolism.
Such differences could suggest causes of statin-induced myotoxi-
city.We also investigated the effect of statins on ubiquinone levels,
and the prenylation and N-linked glycosylation of proteins to fully
determine differences between C2C12 myotube and HepG2 cell
responses to statin treatment. This has not been compared
previously, and would allow a more detailed understanding of
the mevalonate pathway and how statins may lead to skeletal
muscle damage.
2. Materials and methods
2.1. Chemicals
Simvastatin (Sigma–Aldrich, St. Louis, MO, USA) was converted
into theactiveacid followingtheprotocolofBogmanetal. [22]. Stock
solutions of 10 mM simvastatin in DMSO were stored at 20 8C.
Radioactive compounds were supplied by GE Healthcare (Amer-
sham,UK).Webought theToxiLight1assaykit LT07-117 fromLonza
(Basel, Switzerland), the Pierce BCA protein assay kit from Merck
(Darmstadt, Germany) and the Amplex1 Red cholesterol assay kit
from Gibco (Paisley, UK). All other chemicals were supplied by
Sigma–Aldrich (St. Louis, MO, USA), except where indicated.
2.2. Cell culture
C2C12 myoblasts were from the American Type Culture
Collection. We grew the myoblasts in Dubecco’s modified Eagle’s
medium (DMEM) high glucose medium (4.5 g/l) containing 10%
foetal bovine serum (FBS). The myoblasts were seeded at 80,000
cells per well in a 6-well plate, and grown for 2 days. We induced
the myoblasts to differentiate into myotubes using a medium
containing 2% horse serum.We let themyoblasts differentiate for 8
days, and used a medium with no horse serum or FBS for the final
24 h (to induce the cholesterol synthesis pathway). We added
simvastatin at a concentration of 10 mM. DMSO was used as a
control; its concentration was always 0.1%.
We chose the human liver HepG2 cell line as a control. Prof.
Dietrich von Schweinitz (University Hospital Basel, Switzerland)
kindly provided the HepG2 cells. We grew the HepG2 cells in
DMEM low glucose (1 g/l) containing 10% FBS, 1% HEPES and 1%
non-essential amino acids.We seeded 500,000 cells per well in a 6-
well plate. Cells were grown for 1 day, and then the medium was
changed to contain no FBS. The cells were grown in the FBS-
deficient medium for one further day, and simvastatin treatment
was as per the HepG2 cells.
Both cell lines were grown in a humidified incubator with 5%
CO2 at 37 8C.
2.3. Cytotoxicity assay
We used the ToxiLight assay to determine the toxicity of
simvastatin on HepG2 cells and C2C12 myotubes after 1.5, 6 and
18 h. Co-incubation of simvastatin with 100 mM mevalonate,
10 mM farnesol, 10 mM geranylgeraniol or 10 mM squalene, was
used to investigate which branches of the cholesterol synthesis
pathway are important in simvastatin-induced myotube cytotox-
icity. Using luminescence, the kit detected the release of adenylate
kinase from dying cells. Briefly, 20 ml medium was removed after
and mixed with 100 ml ToxiLight reaction buffer. The mixture was
left for 5 min in the dark. Luminescence was measured with a HTS
700 Plus Bio Assay reader and data analyzed with PerkinElmer
HTSoft 2.0 software.
2.4. HMG-CoA reductase activity assay
We followed the protocol of Scharnagl et al. with some
modifications [21]. We added the drug to the cultured cells for 1.5,
6 and 18 h. Culture mediumwas removed after incubation and the
cells washed twice with 1 ml ice-cold wash buffer (50 mM Tris–
HCl, 150 mM NaCl, pH 7.4). Cells were suspended in 1 ml of wash
buffer and centrifuged for 5 min at 2000 rpm at 4 8C. Supernatant
was discarded and cell pellets stored in liquid nitrogen until use.
Simvastatin was therefore no longer present, and enzyme
induction could be measured.
After defrosting on ice, cells were resuspended in 125 ml lysis
buffer (50 mM K2HPO4, 5 mM EDTA Na2, 0.2 mM KCl, 1% Triton X-
100, 5 mM dithiothreitol, pH 7.4) and incubated for 10 min at 37 8C
and 300 rpm. We centrifuged the lysate for 2 min at 13,000 rpm,
and transferred the supernatant to new tubes.We adjusted protein
levels to 2 mg/ml with lysis buffer and added 624mM [14C]-HMG-
CoA (4mCi/ml). The reaction mixture was as described by
Scharnagl et al. [20].
We incubated the samples for 90 min at 37 8C, and then added
20 ml HCl to stop the reaction. We added 20 ml [3H]-mevalono-
lactone (2.27 nCi/ml) as an internal standard, and 50 ml mevalo-
noactone (0.1 mg/ml) to enable visualisation during thin-layer
chromatography (TLC).
Each sample had 1 g of dried sodium sulphate added and
was extracted 3 times for 10 min with diethylether. The ether
phases were collected and evaporated under N2 at 37 8C. We
suspended the residue in 100 ml ice-cold chloroform:methanol
(2:1 by volume).
We separated the samples using TLC with a mobile phase of
toluene:acetone (1:1 by volume). Plates were developed with
iodine and the mevalonoactone spots scraped and dissolved in
1.2 ml H2O. Radioactivity wasmeasured using a liquid scintillation
counter. Data were expressed as nmol of [14C]-mevalonoactone
produced per hour and per milligram of total cell protein.
2.5. Production of esterified and unesterified cholesterol
We incubated the cellswith simvastatin for 6 and 18 h. After the
first 30 min of incubation, we added 10 ml of 2-[14C]-acetate
(2mCi/ml medium) to the cells. After incubation, we removed the
medium and washed the cells twice with buffer A (150 mM NaCl,
50 mM Tris–HCl, 2 mg/ml bovine serum albumin, pH 7.4) and once
with buffer B (150 mM NaCl, 50 mM Tris–HCl, pH 7.4). Cells were
harvested with isopropanol:hexane (2:3 by volume), and 10 ml of
[3H]-cholesterol (1mCi/ul in toluene) added as an internal
standard. We extracted the lipids for 15 min. The samples were
centrifuged for 10 min at 4000  g, and the supernatant evaporat-
ed to dryness under N2. The protein pellet was dissolved in 1 ml of
0.1N NaOH and 2% SDS, and used for protein determination. We
resuspended the residue in 100ml chloroform:methanol (1:1 by
volume) and separated the lipids via TLC with a solvent of
hexane:diethylether:formic acid (40:15:1 by volume). Cholesterol
and cholesterol ester standards were run concurrently, to enable
identification of the correct spots. We developed the plates with
iodine, cut out the spots containing esterified and unesterified
cholesterol, and dissolved them in 1 ml H2O. A liquid scintillation
counter determined radioactivity and results were expressed as
nmol of [14C]-acetate incorporated per hour and per milligram of
total cell protein.
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2.6. Measurement of total cell cholesterol
Cells were incubated with simvastatin for 6 and 18 h. We
removed cell medium and washed 3 times with 500ml PBS. We
used hexane:isopropanol (3:2 by volume) to extract lipids.
Extraction was for 15 min. We then added 500ml chloroform
(containing 2% Triton X-100) to enhance extraction. We centri-
fuged the samples for 5 min at 3000 rpm, and dried the organic
layer under N2.We resuspended the extracted lipids in 300 ml H2O.
We used the Amplex Red kit to determine levels of free and total
cholesterol. Plates were incubated at 37 8C in the dark, and
fluorescence measured on a Spectra Max Gemini at 530–560 nm
and an emission of 590 nm. We ran the samples with and without
esterases to allow quantification of cholesterol esters and free
cholesterol.
2.7. LDL receptor expression
Simvastatin incubation was for 1.5, 6 and 18 h.We removed cell
mediumand lysed thecellswith350ml RLTbuffer (Qiagen,Valencia,
CA, USA). We transferred the lysate to Qiashredder columns and
centrifuged for 2 min at 13,000 rpm. The flow-through was purified
using the Qiagen RNeasymini extraction kit, with a DNA digest step
to ensure pure RNA. We synthesized cDNA using the Qiagen
omniscript system, and used 10 ng of the cDNA for quantitative RT-
PCR. We used a primer–probe assay on demand for LDL receptor
from Applied Biosystems, Foster City, CA (Mm01177349_m1 and
Hs0018192_m1). We calculated relative quantities of specifically
amplified cDNA with the comparitive-threshold cycle method.
GAPDH acted as endogenous reference (Eurogentec, Seraing,
Belgium). No-template and no-reverse-transcription controls en-
sured nonspecific amplification could be excluded.
2.8. Total ubiquinone quantification
We used the method of Cordoba-Pegrosa et al. to quantify total
ubiquinone levels [23]. We grew the cells in 175 cm2 flasks. We
incubated the cells with simvastatin for 1.5, 6 or 18 h. We then
removed the medium and washed the cells twice with 10 ml ice-
cold 0.9% NaCl. We used 2 ml 1% SDS to solubilize the cells, and
added 4 ml ethanol:isopropanol (95:5 by volume).We added 25 ml
menaquinone (diluted 1:10 in methanol) as an internal standard.
We mixed the samples with 10 ml of hexane, vortexed 5 times for
1 min, and centrifuged at 1000 rpm for 5 min. We recovered the
upper organic phase and repeated the extraction twice. The hexane
fractions were evaporated to dryness under N2 and resuspended in
250 ml methanol.
We quantified total ubiquinone levels with high-performance
liquid chromatography using a reverse phase C-18 column. The
mobile phase was methanol:isopropanol (2:1 by volume), and we
used a flow rate of 0.7 ml/ml, an injection volume of 20 ml and UV
detection at 275 nm. Data were analyzed with EZChrom Elite
software version 3.1.5. We ran a standard curve with the samples
to allow quantification.
2.9. Western blot of SREBP-2, Ras and Rap1
After simvastatin incubation for 1.5, 6 and 18 h, we removed
the medium and washed twice with 1 ml PBS. We lysed the cells,
for 15 min on ice, with 200 ml NET lysis buffer (0.05 M Tris–HCl pH
8.0, 50 mM NaCl, 5 mM EDTA, 1% NP-40 and protease inhibitor
tablet). The samples were vortexed and then centrifuged for
10 min at 13,000 rpm at 4 8C. We collected the supernatant and
determinedprotein levels. This represented thewhole cell protein
fraction.We separated the proteins (50 mg for SREBP-2 and 20 mg
for Ras and Rap1) on a denaturing SDS polyacrylamide gel (4%
stacking, 10% separating for SREBP-2, and a 4–12% gradient for Ras
and Rap1). We blotted the proteins to either nitrocellulose
membranes (SREBP-2) or polyvinylidendifluoride membranes
(Ras and Rap1). We used an antibody against SREBP-2 that
recognizes both the mature and immature proteins, thereby
removing the need to fractionate the protein lysate (1:1000
dilution, BD Biosciences, Franklin Lakes, NJ). The Ras, Rap1 and
Rap1A antibodies were at a 1:250 dilution (Ras from BD
Biosciences, Rap1 and Rap1A from Santa Cruz Biotechnology,
USA). Peroxidase-labelled anti-mouse, anti-goat and anti-rabbit
antibodies, and chemiluminescence substrate (GE Healthcare)
were used for analysis. Rap1, Rap1A and Ras antibodies were also
used on protein lysates from 18 h treatment with FTI-277 and
GGTI-2133.
2.10. N-linked glycosylation
We followed the protocol of Larsson et al. to determine the rate
of N-linked glycosylation [24]. Briefly, we added 5ml [3H]-
glucosamine to the cell medium for the final 4 h of simvastatin
incubation. After simvastatin incubation for 6 or 18 h, we removed
the medium and washed twice with 1 ml PBS. We lysed the cells,
for 15 min on ice, with 200 ml NET lysis buffer (0.05 M Tris–HCl pH
8.0, 50 mM NaCl, 5 mM EDTA, 1% NP-40 and protease inhibitor
tablet). The samples were vortexed and then centrifuged for
10 min at 13,000 rpm at 4 8C. We collected the supernatant and
added 50 ml 100% TCA to precipitate the proteins. The precipitate
was washed twice with 10% TCA, collected with 1.2 ml H2O and
dissolved in scintillation fluid. Radioactivity was measured on a
liquid scintillation counter.
2.11. Statistical evaluation
All results are expressed as mean  SD and evaluated with
Student’s t-test, where p values of <0.05 considered significant.
3. Results
3.1. Cytotoxicity
We measured the release of AK from cells to determine the
cytotoxicity of simvastatin (Fig. 1). Prior work in our lab showed
that 10 mM simvastatin was the lowest concentration that led to
widespread cell death of C2C12myotubes after 48 h. A subsequent
Fig. 1. Toxicity of 10mM simvastatin on C2C12 myotubes and HepG2 cells. C2C12
myotubes (black bars) and HepG2 cells (white bars) were incubated with 10mM
simvastatin for the times indicated. We measured the release of AK into the
medium. DMSO-treated cells were used as a control. Results are expressed as ratios
to the DMSO control. Each C2C12 bar represents the mean of five independent
experiments carried out in duplicate. Each HepG2 bar represents the mean of three
independent experiments carried out in duplicate. **p < 0.01 versus control.
P.J. Mullen et al. / Biochemical Pharmacology 79 (2010) 1200–12091202
time course experiment observed the first significant increase in
toxicity at 18 h (data not shown). We have now observed no
significant toxicity after 1.5 or 6 h. C2C12 myotubes treated with
simvastatin for 18 h had a significant increase in AK release of 1.37-
fold compared to control cells. We did not observe any significant
toxicity on the HepG2 cells at any timepoint. We then added
intermediates of the cholesterol synthesis pathway and measured
cytotoxicity. This would determine the relative importance of each
branch of the cholesterol synthesis pathway in simvastatin-
induced cytotoxicity. Co-incubation of simvastatin with mevalo-
nate or geranylgeraniol rescued C2C12 myotubes from cytotoxici-
ty, whereas farnesol rescued to a lesser extent. Squalene did not
rescue the C2C12 myotubes (Table 1).
3.2. HMG-CoA reductase activity
Inhibition of the cholesterol synthesis pathway with simva-
statin has been previously shown to increase levels of HMG-CoA
reductase in HepG2 cells [25]. This has not been investigated in
C2C12 myotubes. We used protein lysates from simvastatin-
treated cells to determine HMG-CoA reductase activity. This
removed simvastatin from the system, and allowed us to
determine if levels of HMG-CoA reductase changedwith treatment
time. Addition of [14C] HMG-CoA, followed by quantification of
[14C] mevalonate production, enabled determination of enzyme
activity. C2C12 myotubes showed an initial reduction in enzyme
activity to 50% of control myotubes after 1.5 h (Fig. 2a). The level of
inhibition reduced over time so that after 18 h enzyme activitywas
71% of control. HepG2 cells showed an inhibition to 64% of control
after 1.5 h treatment with simvastatin (Fig. 2b). Treatment for 18 h
resulted in an increase of enzyme activity to 356% of control,
representing a strong induction in HMG-CoA reductase expression
or activity.
3.3. De novo synthesis of cholesterol and cholesterol esters, and total
cellular cholesterol pool
We examined the effect of simvastatin on the biosynthesis of
unesterified cholesterol and cholesterol esters in C2C12 myotubes
and HepG2 cells. Incorporation of [14C] acetate determined the
rates of synthesis. Simvastatin reduced free cholesterol production
in C2C12 myotubes (to 6% after 6 h and 5% after 18 h; Fig. 3a). We
observed a weaker reduction in the HepG2 cells (to 19% at 6 h and
18% at 18 h; Fig. 3b). HepG2 cells produced nearly 10-fold more
cholesterol than C2C12 myotubes. Cholesterol ester synthesis
dropped slightly in C2C12 myotubes after 6 h treatment (Fig. 3c).
After 18 h, cholesterol ester synthesis dropped to only one third of
control cells. In contrast, we observed almost complete inhibition
of HepG2 cell cholesterol ester synthesis after 6 and 18 h (Fig. 3d).
We also measured the total cellular cholesterol concentrations
to determinewhether the strong inhibition of cholesterol synthesis
influences the overall cholesterol pool in both cell lines. Both cell
lines showed no variation in free or esterified cholesterol content
after treatment with simvastatin (Fig. 4). The composition of the
cholesterol pool was different in the two cell lines, C2C12
myotubes contained more free cholesterol than the HepG2 cells
(by around 1.5-fold).
3.4. LDL receptor expression
In the body, the liver compensates for a reduction in cholesterol
synthesis by up-regulating the expression of the LDL receptor,
scavenging circulating LDL particles. It is not known if this occurs
in skeletal muscle. Quantitative RT-PCR determined the impact of
simvastatin treatment on LDL receptor mRNA expression levels.
The C2C12 myotubes showed no increase in LDL receptor mRNA
expression (Fig. 5a). LDL receptor mRNA expression in HepG2 cells
increased 1.8-fold after 6 h treatment, and 2.7-fold after 18 h
treatment (Fig. 5b).
3.5. SREBP-2 activation
Cleaved mature SREBP-2 relocates to the nucleus to act as a
transcription factor. It regulates the transcription of genes involved
in cholesterol synthesis and uptake, such as hmgr and ldlr. We used
Western blotting to detect the mature and immature forms of the
SREBP-2 transcription factor. The antibody detected both the
immature protein and the cleaved active mature form. Mature
SREBP-2 substantially increased in HepG2 cells treated with
simvastatin (Fig. 6c). This correlates with the corresponding
increase in LDL receptor expression and HMG-CoA reductase
activity. SREBP-2 was not expressed in the C2C12 myotubes. Both
Table 1
Rescue of simvastatin toxicity in C2C12 myotubes by co-incubation with
cholesterol pathway intermediates.
Co-incubation Rescue (mean% SD)
Mevalonate (100mM) 89.6610.39*
Farnesol (10mM) 57.756.39*
Geranylgeraniol (10mM) 92.3720.06*
Squalene (10mM) 21.2223.09
Cells were incubated with 10mM simvastatin plus the treatments shown,
and AK release into medium was measured. 0%=no rescue when
compared to cells treated with simvastatin only; 100%=complete rescue
(back to values of DMSO-treated controls). Results are means of four
independent experiments in triplicate.
* p<0.01 versus control.
Fig. 2. Effect of 10mM simvastatin on HMG-CoA reductase activity. Cells were
incubated with DMSO (black bars) or simvastatin (white bars) for the indicated
times. Protein lysate was collected and enzymatic activity assay performed. Results
are for (A) C2C12 myotubes and (B) HepG2 cells. The data represents the mean of
four experiments carried out in duplicate. *p < 0.05 and **p < 0.01 versus control.
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cell lines expressed SREBP-1, but simvastatin treatment did not
alter the levels of mature SREBP-1 (data not shown).
3.6. Total cellular ubiquinone pool
Ubiquinone synthesis is also dependent upon the cholesterol
synthesis pathway. The effect of simvastatin treatment on total
ubiquinone levels was determined using HPLC. The major
ubiquinone in HepG2 cells was CoQ10, whereas C2C12 myotubes
contained a majority of CoQ9. This represents the species
difference between humans and mice. Total ubiquinone levels
did not alter in simvastatin-treated C2C12 myotubes (Fig. 7a).
Simvastatin-treatedHepG2 cells exhibited reduced CoQ10 levels in
a time-dependentmanner. A significant reduction to 73% of control
occurred after 18 h (Fig. 7b).
3.7. Protein prenylation
Post-translational prenylation of proteins requires the choles-
terol synthesis pathway intermediates geranylgeranyl pyrophos-
phate and farnesyl pyrophosphate.We used Ras as a representative
of farnesylated proteins and Rap1 to represent the geranylger-
anylated proteins. We used two antibodies to determine the
geranylgeranylation state of Rap1, one detected all Rap proteins
and the other only ungeranylgeranylated Rap1. Overall levels of
Rap1 remained constant in both cell lines during simvastatin
treatment (Fig. 8a and c). Ungeranylgeranylated Rap1 was only
present in C2C12 myotubes and HepG2 cells treated with
simvastatin (Fig. 8b and d). The proportion of ungeranylgerany-
lated Rap1 increased as treatment time increased. This effect was
Fig. 3. Effect of 10 mM simvastatin on production of cholesterol in C2C12
myotubes and HepG2 cells. Cells were incubated with DMSO (black bars) or
simvastatin (white bars) for the times indicated. 2-[14C]-acetate was added
30 min after start of drug incubation. The graphs show production of cholesterol
in (A) C2C12 myotubes and (B) HepG2 cells. Cholesterol ester production is
shown for (C) C2C12 myotubes and (D) HepG2 cells. The HepG2 results are
means of four independent experiments carried out in duplicate. The C2C12
results are means of five independent experiments in duplicate. *p < 0.05 and
**p < 0.01 versus control.
Fig. 4. Effect of 10 mM simvastatin on cellular lipid content. Cells were incubated
with DMSO or simvastatin for the times indicated. The graphs show free cholesterol
(black bars) and cholesterol ester concentrations (white bars) in (A) C2C12
myotubes and (B) HepG2 cells. Data are means of four independent experiments
carried out in duplicate.
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reversed upon co-incubation with GGOH (data not shown).
Incubation with the geranylgeranylation inhibitor GGTI-2133 also
led to an expected increase in ungeranylgeranylated Rap1 in C2C12
myotubes (Fig. 10a and b). Similar results were observed with
GGTI-treated HepG2 cells (data not shown).
We determined alterations in farnesylation by comparison of
Ras protein size on a Western blot. Unfarnesylated Ras has a
higher molecular weight than farnesylated Ras due to cleavage of
the last three carboxy terminal residues. This difference can be
detected using one antibody [26]. Both cell lines showed higher
weight Ras protein after 18 h treatment with simvastatin,
indicating a reduction in farnesylation (Fig. 9). Co-incubation
with FOH increased the farnesylation of Ras in both cell lines
treated with simvastatin (data not shown). Incubation with the
farnesylation inhibitor FTI-277 also reduced the level of farne-
sylated Ras in C2C12 myotubes (Fig. 10c). We saw similar results
with HepG2 cells treated with the FTI (data not shown).
3.8. N-linked glycosylation
Dolichol is produced from the cholesterol synthesis pathway,
and is vital in anchoring N-linked sugars to proteins and ensuring
correct protein function. We determined the rate of N-linked
glycosylation in simvastatin-treated cells via addition of [3H]-
glucosamine. Treatment of HepG2 cells with simvastatin did not
alter incorporation of [3H]-glucosamine into proteins. C2C12
myotubes showed a significant reduction in [3H] glucosamine-
labelled proteins after 18 h treatment to 79% of control, and
therefore a reduction inN-linked glycosylation of proteins (Fig. 11).
4. Discussion
Statins inhibit HMG-CoA reductase, the rate-limiting enzyme in
cholesterol biosynthesis [3,4]. Statins exert their effects primarily
in the liver, where they are well-tolerated and not toxic, whereas
skeletal muscle is the site of the majority of side effects observed
with statins [5–8]. We aimed to compare responses to simvastatin
in liver HepG2 cells and skeletal muscle C2C12 myotubes.
Differences between the two cell lines could indicate the
Fig. 5. Effect of 10mM simvastatin on LDL receptormRNA expression. Total RNAwas
extracted from cells after treatment with DMSO (black bars) or simvastatin (white
bars). Expression was measured by quantitative RT-PCR with GAPDH as an
endogenous control. Expression after simvastatin treatment is shown as a ratio of
expression in DMSO-treated control cells. Ratios are for (A) C2C12myotubes and (B)
HepG2 cells. The results are the mean of four experiments carried out in triplicate.
*p < 0.05 and **p < 0.01 versus control.
Fig. 6. Effect of 10mM simvastatin on SREBP-2 transcription factor expression and
processing. Total protein was extracted after treatment with DMSO or simvastatin.
Actin was used to confirm equal loading. SREBP-2 expression is only shown for
HepG2 cells. Results are indicative of three independent experiments.
Fig. 7. Effect of 10 mM simvastatin on cellular ubiquinone concentration. Cells
were incubated with DMSO or simvastatin for 1.5, 6 or 18 h. Total cellular
ubiquinone was extracted and measured by HPLC. Total CoQ9 (black bars for
DMSO and dark grey bars for simvastatin) and CoQ10 levels (white bars for DMSO
and light grey bars for simvastatin) are shown for (A) C2C12 myotubes and (B)
HepG2 cells. Results are expressed as the ratio to DMSO control, and represent the
mean of three independent experiments. *p < 0.05 versus control.
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Fig. 8. Effect of 10mM simvastatin on geranylgeranylation of Rap1. Total protein was extracted after treatment with DMSO or simvastatin. Actin was used to confirm equal
loading. Total Rap1 expression is shown for (A) C2C12myotubes and (C) HepG2 cells. Ungeranylgeranylated Rap1 expression is shown in (B) C2C12myotubes and (D) HepG2
cells. Results are indicative of three independent experiments.
Fig. 9. Effect of 10 mM simvastatin on farnesylation of Ras. Total protein was extracted after treatment with DMSO or simvastatin. Actin was used to confirm equal
loading. Ras expression is shown for (A) C2C12 myotubes and (B) HepG2 cells. The upper bands represent unfarnesylated Ras protein. Results are indicative of three
independent experiments.
Fig. 10. Effect of FTI and GGTI incubation on prenylation of Rap1 and Ras in C2C12myotubes. Total protein was extracted from C2C12myotubes treated for 18 h with DMSO,
simvastatin, FTI or GGTI. Expression of (A) Rap1, (B) Rap1A and (C) Ras is shown.
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mechanism behind statin-induced myopathy. We confirmed that
10 mM simvastatin has a significant toxic effect in the C2C12 cell
line [27]. This toxicity was not observed in the HepG2 cell line,
which suggests that our system adequately represents the in vivo
situation. In contrast, Tavintharan et al. found that treatment for
18 hwith 10 mM simvastatin is toxic to HepG2 cells [28]. The 10 mM
simvastatin we used is higher than would be expected in the
plasma of patients, where values of up to 1mM are observed.
However, localized concentrations in skeletal muscle could be
higher than the observed plasma levels, especially when combined
with fibrates or cytochrome P450 inhibitors [29]. The rescue of the
C2C12 myotubes by mevalonate confirms that statin-induced
toxicity is a direct result of inhibition of the cholesterol synthesis
pathway, and not an off-target effect.
Statins exert their therapeutic effects via a reduction of
circulating LDL levels. Statins reduce the production of cholesterol
in the liver, leading to a SREBP-2-dependent increase in LDL
receptor expression and scavenging of circulating LDL [3,4]. How
statins affect cholesterol metabolism in skeletal muscle has not
been previously investigated. We addressed this using C2C12
myotubes.
Simvastatin inhibited HMG-CoA reductase in cultured cells, as
seen by the drop in the rate of unesterified and esterified
cholesterol synthesis in both HepG2 cells and C2C12 myotubes.
This confirms the findings of a study by Scharnagl et al. on HepG2
cells [20]. We showed that HepG2 cells compensated for this
inhibition by up-regulating the HMG-CoA reductase enzyme, but
the high concentration of simvastatin meant that inhibition still
occurred. This can be explained by the observed increase inmature
SREBP-2, leading to an increase in transcription of HMG-CoA
reductase. No up-regulation of HMG-CoA reductase occurred in the
C2C12myotubes, probably because of the lack of expression of the
SREBP-2 transcription factor in this cell line. Despite the drop in
cholesterol synthesis, total cellular cholesterol levels were not
reduced in either cell line. Cholesterol turnover may, however,
need longer than the 18 h incubation we used until changes are
detected. Two other mechanisms might also explain our observa-
tion that total cholesterol levels do not change in statin-treated
cells: (1) increased receptor-mediated uptake of LDL particles from
the medium, and (2) a reduced efflux of cholesterol-containing
particles. Since we used starvation medium lacking FBS it seems
unlikely that the cells keep their cholesterol levels constant via
uptake of cholesterol, thus the second hypothesis seems more
plausible. Previous studies also show that statin treatment leads to
reduced secretion of cholesterol-containing lipoproteins from
HepG2 cells [20]. Reduced efflux of cholesterol could helpmaintain
total cellular cholesterol levels during in vitro statin treatment.
DMSO-treated cells would still maintain the regular lipid efflux.
This could explain why total cholesterol levels are unchanged
between statin-treated cells and those treated with DMSO, even
though cholesterol synthesis is greatly reduced under simvastatin
treatment. This means that the myotubes are not dying as a result
of cholesterol depletion, and adds weight to the hypothesis that
suggests myopathy is not primarily caused by lowering of
cholesterol. We did not observe any increase in LDL receptor
mRNA expression in the C2C12 myotubes. This can again be
explained by the lack of expression of the transcription factor
SREBP-2 in this cell line. This is in stark contrast to HepG2 cells, in
which we confirm earlier work which shows statins up-regulate
LDL receptor mRNA expression [20,30]. Others have shown statin
toxicity to be a cholesterol-independent event [31,32]. Flint et al.
inhibited squalene synthase, which is downstream fromHMG-CoA
reductase and is only involved in cholesterol synthesis. They did
not observe toxicity in rat muscle cultured and treated with
squalene synthase inhibitors in vitro [31]. We confirm this
observation by showing that co-incubation of simvastatin with
squalene does not prevent toxicity. The compounds produced from
the squalene synthase-independent branches of the cholesterol
synthesis pathway are involved inmany diverse cellular processes,
and therefore are attractive candidates for causing myopathies.
One candidate compound is ubiquinone, which is an electron
carrier in the electron transport chain. Depletion of ubiquinone
plays a role in some mitochondrial myopathic diseases [33,34].
Folkers et al. amongst others, hypothesized that statins could
deplete ubiquinone levels, leading to mitochondrial dysfunction,
disruption of cellular energy supplies and apoptosis [35,36].
Previous work in our lab shows simvastatin to only affect the
electron transport chain at high concentrations (50 mM) [37]. This
study has expanded on that observation and found no evidence
that simvastatin reduces total cellular ubiquinone content in
C2C12 myotubes. This is the first such study in C2C12 myotubes
and is consistent with previous studies in other systems [14,38].
This result also complements studies in humans, which show
ubiquinone supplementation does not reverse myopathy during
statin treatment [39,40]. We did observe a decrease in HepG2
CoQ10 levels, but this did not lead to any observable toxicity,
suggesting that the electron transport chain can still function with
a 27% decrease in cellular CoQ10 levels. In comparison,
Tavintharan et al. show that larger drops in cellular CoQ10 is
associated with toxicity in HepG2 cells [28]. Taken together,
ubiquinone levels do not appear to be relevant to statin-induced
myopathy.
Post-translational prenylation of proteins is also dependent on
the cholesterol synthesis pathway [9]. The addition of a farnesyl or
geranylgeranyl moiety is important for correct localization of
proteins, particularly of small GTPases such as Ras and Rap1 [41].
These proteins play critical roles in multiple signalling pathways
controlling cell growth, repair, differentiation and cellular adhe-
sion. Statins are known to inhibit both farnesylation and
geranygeranylation in a variety of cell lines [31,41]. We have
shown that simvastatin increased levels of unfarnesylated Ras and
ungeranylgeranylated Rap1 in both cell lines.We did not, however,
observe any HepG2 toxicity, indicating that impaired prenylation
of Ras and Rap1 has no impact on cell survival in these liver cells.
We hypothesize that, in contrast to HepG2 cells, incorrect
localization of small GTPases could lead to altered signalling
and cell death in C2C12 myotubes. The importance of prenylation
was further seen by geranylgeraniol reducing the toxicity of
simvastatin in C2C12 myotubes, a finding that correlates with
previous work [14,42]. Intriguingly, addition of farnesol does not
Fig. 11. Effect of 10mM simvastatin onN-linked glycosylation of proteins. Cells were
incubated with DMSO (black bars) or simvastatin (white bars) for 6 or 18 h, and
pulse-chased with [3H]-glucosamine for the final 4 h. Protein was extracted and the
incorporated radioactivity was measured. Results are expressed as the ratio to
DMSO control, and represent the mean of four independent experiments. *p < 0.05
versus control.
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rescue the cells to the same extent as geranylgeraniol. Cao et al.
also show that specific inhibitors of geranylgeranyltransferase
increase apoptosis, unlike farnesyltransferase inhibitors [42]. This
evidence points to geranylgeranylated proteins playing a large part
in statin-induced myopathy. The large number of prenylated
proteins warrants further investigation into the effects of
dysprenylation caused by statins. Future work in our lab will
determine the actual proteins that, when ungeranylgeranylated,
are associated with myopathy.
N-linked glycosylation is a post-translational modification that
is also dependent upon the cholesterol synthesis pathway [15].
This process requires dolichol, a polyprenol downstream from
farnesyl- and isopentenyl-pyrophosphate. Oligosaccharides need
to be linked to dolichol before they are added to asparagine
residues of target proteins, and dolichol is cleaved during the
linkage to asparagine [15]. No prior studies have looked at how
statins affect N-linked glycosylation in C2C12 myotubes. We
showed that simvastatin reduced the rate ofN-linked glycosylation
in C2C12 myotubes to 80% of control. In contrast, we observed no
reduction in N-linked glycosylation in HepG2 cells. This suggests
that aberrant N-linked glycosylation may have a role in statin-
induced toxicity in C2C12 myotubes, although which proteins are
affected is not yet known.
Glycosylation of proteins is crucial for correct function of many
proteins. It increases protein stability and facilitates interactions
between proteins and ligands [43]. Previous studies implicate
statins in aberrant processing of N-linked glycoproteins [44–49].
One such protein is the Igf1 receptor. This receptor requires correct
N-linked glycosylation before it can be cleaved from the
proreceptor to the mature receptor [47–49]. Statins increase
levels of proreceptor, decrease the expression of mature Igf1
receptor at the cell surface and promote apoptosis in Ewing’s
sarcoma cells [50]. We aim to investigate whether this also occurs
in skeletal muscle cells.
The glycoprotein a-dystroglycan, which is part of a complex
that anchors the cytoskeleton to the extracellular matrix, is also
heavily glycosylated [16,19]. It is also implicated in many of the
congenital muscular dystrophies, which can be caused by aberrant
glycosylation of proteins [18]. Although there is more O-linked
than N-linked glycosylation on a-dystroglycan, insufficient N-
linked glycosylation may contribute to congenital muscular
dystrophies. A reduction in N-linked glycosylation of a-dystro-
glycan, caused by statins, could potentially affect the skeletal
muscle and lead to myopathy.
Furtherwork is required to fully determine the proteins that are
affected by aberrant N-linked glycosylation under statin treat-
ment. Linking these future studies to those investigating altered
small GTPase function could lead to breakthroughs in understand-
ing statin-induced myopathies, and is a direction we aim to
undertake.
Our data showed for the first time that total cholesterol and
ubiquinone contents are not altered by simvastatin in C2C12
myotubes, and are therefore not likely to associate with statin-
induced myotoxicity. Overall, the inhibition of HMG-CoA reduc-
tase by statins can also affect the production of numerous
compounds other than cholesterol and ubiquinone. Our compari-
son between C2C12 myotubes and HepG2 cells allows us to
suggest that the skeletal muscle side effects of statins may be
related, at least in part, to cholesterol-independent effects,
particularly reductions in prenylation or N-linked glycosylation
of proteins.
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5.  Abstract 
Statins are widely used to prevent cardiovascular diseases. They are well-tolerated, with side-
effects mainly seen in skeletal muscle. How these side-effects are caused is unknown. We 
compared isolated primary mouse skeletal muscle myocytes, C2C12 myotubes and liver HepG2 
cells to uncover differences that could uncover why statins are toxic in skeletal muscle but not 
the liver. 10 µM simvastatin caused a decrease in mitochondrial respiration and glycolysis in the 
primary mouse myocytes and C2C12 myotubes, but had no effect in the HepG2 cells. 
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Mitochondrial integrity is maintained by multiple signalling pathways. One of these pathways, 
Igf-1/Akt signalling, is also heavily implicated in causing statin-induced toxicity by upregulating 
atrogin-1. We found phosphorylated Akt was reduced in C2C12 myotubes but not in HepG2 
cells. HepG2 mitochondrial respiration became susceptible to simvastatin-treatment after Akt 
inhibition, and mitochondrial respiration was rescued in Igf-1-treated C2C12 myotubes. These 
results suggest disruption of Igf-1/Akt signalling is a causative factor in simvastatin-induced 
mitochondrial dysfunction in C2C12 myotubes, whereas HepG2 are protected by maintaining 
Igf-1/Akt signalling. How statins can disrupt Igf-1/Akt signalling is unknown. Statins reduce 
geranylgeranylation of small GTPases, such as Rap1. Previous studies implicate Rap1 as a link 
between cAMP/Epac and Igf-1/Akt signalling. Transient transfection of constitutively active 
Rap1 into C2C12 myotubes led to a partial rescue of simvastatin-induced inhibition of 
mitochondrial respiration. There was however, no reduction in atrogin-1 levels, although 
nuclear translocation of Foxo3a was reduced. We conclude that phosphorylation of Akt is a key 
indicator of susceptibility to statin-induced toxicity. 
5.1. Introduction 
Statins are among the most prescribed drugs in Western countries. They reduce 
morbidity and mortality from coronary heart disease and mitigate the risk of stroke.1,2 
Their major site of action is the liver, where they inhibit HMG-CoA (hydroxyl-methyl-
glutaryl-coenzyme A) reductase, the rate-limiting step in cholesterol biosynthesis.3  
Inhibition of this pathway also inhibits various other processes, such as ubiquinone 
production and the isoprenylation and N-linked glycosylation of proteins.4–6  Altering 
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these processes can reduce inflammation, oxidative stress and platelet adhesion – 
leading to the positive effects of statins.7,8  
Statins are generally well tolerated but there are dose-dependent side-effects, 
particularly in skeletal muscle where myopathy is seen in 1–5% of patients.9,10  Statin-
induced side effects are rarely observed at their site of action in the liver. We have 
previously showed that the human liver HepG2 cell line is not susceptible to 
simvastatin toxicity, and consider this a viable model to uncover mechanisms of 
resistance to simvastatin-induced toxicity.6   Two possible mechanism of toxicity 
involve disrupting mitochondrial health, and upregulating atrophy-inducing 
proteins.11,12 
Studies in various tissues show statins can affect the mitochondria directly, via 
inhibition of the respiratory chain complexes, or indirectly via lowering of ubiquinone 
levels.13,14  We have already showed that statins can alter mitochondrial function in 
skeletal muscle.11  It is not known whether statins can affect mitochondrial respiration in 
liver cells. We aim to check for any differences between mitochondrial respiration in 
C2C12 myotubes and liver HepG2 cells. Mouse C2C12 myotubes are a well-established 
in vitro model of skeletal muscle.6  Uncovering differences could provide key insights 
into what makes certain cell lines resistant to statin toxicity whereas other cell lines are 
susceptible. 
Mitochondrial health is maintained, part, by multiple signalling pathways.15–17  Some 
groups have suggested that impairment in cell signalling is a major cause of statin-
induced myotoxicity.18-20  One pathway of great interest is the Igf-1/Akt pathway. It is 
already known that this pathway is integral to mitochondrial health, and its impairment 
has also been implicated as a contributing factor in statin toxicity.21–24  We therefore aim 
to discover whether any potential differences in the mitochondria of simvastatin-treated 
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C2C12 myotubes and HepG2 cells can be explained by differences in Igf-1/Akt 
signalling. 
Baviera et al. suggest that a geranylgeranylated protein, Rap1, could potentiate Igf-
1/Akt signalling.25  We therefore aim to express constitutively active Rap1 in C2C12 
myotubes to discover whether it can rescue the myotubes from simvastatin-induced 
mitochondrial toxicity. This would increase our knowledge of how simvastatin leads to 
mitochondrial toxicity, and how it can affect signalling through the Igf-1/Akt pathway. 
Igf-1/Akt signalling is also vital in protecting skeletal muscle from atrophy, and statin-
induced reductions in signalling lead to an increase in levels of the atrophy-inducing 
protein atrogin-1 in skeletal muscle.12  This increase in atrogin-1 levels is reversible by 
the addition of compounds leading to geranylgeranylation (such as geranylgeranyl 
pyrophosphate, GGPP).26  We will therefore investigate if expression constitutively 
active Akt can prevent the upregulation of atrogin-1 in C2C12. 
These experiments will increase our understanding of how statins lead to mitochondrial 
toxicity, the role that Igf-1/Akt signalling plays in that, and whether Rap1 mediates the 
change in Igf-1/Akt signalling. 
5.2. Materials and methods 
5.2.1. Chemicals 
Simvastatin (Sigma-Aldrich, St. Louis, MO, USA) was converted into the active acid 
following the protocol of Bogman et al.27  Stock solutions of 10 and 100 mM simvastatin 
in DMSO were stored at –20°C. The ToxiLight® assay kit LT07-117 was from Lonza 
(Basel, Switzerland) and the Pierce BCA protein assay kit from Merck (Darmstadt, 
Germany). Antibodies to FoxO1, FoxO3a, Akt and P-Akt were provided by Cell 
Signaling Technology (Danvers, MA, USA). The Alexa Fluor® secondary antibodies 
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were from Invitrogen (Basel, Switzerland). All other chemicals were supplied by Sigma-
Aldrich (St. Louis, MO, USA), except where indicated. 
5.2.2. Primary neonatal mouse myoblast culture 
We took skeletal muscle from the hind limbs of neonatal BL6 mice (kindly provided by 
Prof. Daniel Bodmer, University Hospital Basel), and isolated mouse myoblasts using a 
protocol modified from Springer et al.28  Briefly, we digested the skeletal muscle with 
sequential trypsinisation and trituration. We plated the cells for an hour, during which 
the non-myocytes adhered to the plate, and collected the enriched suspension of 
myocytes. Myocytes were then suspended in Ham’s F10 medium supplemented with 
20% FBS, 2% L-glutamine, 1% bicarbonate and 1% pen/strep. We added 2 ng/ml bFGF to 
prevent the proliferation of non-myocytes. The myoblasts were seeded at a density of 
5,000 cells per well of a 96-well plate coated with collagen I. After 24 h, the 
concentration of bFGF was increased to 5 ng/ml. Differentiation was induced by 
changing to Ham’s F10 medium containing 5% horse serum. 
5.2.3. Cell culture 
C2C12 myoblasts were from the American Type Culture Collection. We grew the 
myoblasts in Dulbecco modified Eagle’s medium (DMEM) high-glucose medium (4.5 
g/l) containing 10% FBS and 5 mM HEPES. The myoblasts were seeded at 150,000 cells 
per well in a 6-well plate (or equivalent), and grown for 3 days to achieve confluence. 
We induced the myoblasts to differentiate into myotubes using a medium containing 
2% horse serum. The myotubes were fully differentiated after 3 days, after which 
treatment occurred for 6 h. We added simvastatin at a concentration of 10 µM and other 
compounds at the concentrations indicated. DMSO was used as a control; its 
concentration was always 0.1%.  
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The human liver HepG2 cell line was kindly provided by Prof. Dietrich von Schweinitz 
(University Hospital Basel, Switzerland). We grew the HepG2 cells in DMEM low 
glucose (1 g/l) containing 10% FBS, 1% HEPES and 1% non-essential amino acids. We 
seeded 500,000 cells per well in a 6-well plate (or equivalent). Cells were grown for 1 
day, and then treated with the relevant compounds for 24 h. 
Both cell lines were grown in a humidified incubator with 5% CO2 at 37°C. 
5.2.4. Transfection of C2C12 myoblasts 
The pEGFP-C3 plasmid (Clontech, CA, U.S.A.) containing constitutively active Rap1, 
and the empty plasmid, were kindly provided by Prof. Mark R. Philips (New York 
University School of Medicine). C2C12 myoblasts were seeded as before, and grown for 
1 day, before transfection using Lipofectamine 2000 (Invitrogen, CA, U.S.A.). Cells were 
then allowed to grow as normal, and differentiate into myotubes. Approximately equal 
numbers of GFP-expressing myotubes were obtained with both plasmids. 
5.2.5. Detection of apoptosis after simvastatin treatment 
We used an in situ apoptosis detection kit for Annexin V binding and propidium iodide 
(PI) staining (VybrantTM Apoptosis Assay Kit #2, from Invitrogen). After incubation 
with simvastatin, we stained detached cells with 5 µl Annexin V-AlexaFluor 488 and 1 
µl PI (final concentration 1 µg/ml) in Annexin V buffer as per the kit protocol. The 
samples were incubated for 15 minutes and analysed by flow cytometry, using a DAKO 
Cyan cytometer. 
5.2.6. Measurement of mitochondrial membrane potential 
We used tetramethylrhodamine, ethyl ester, perchlorate (TMRE; Invitrogen) to detect 
changes in mitochondrial membrane potential (ψm).29  Cells were incubated with 
simvastatin, then detached and incubated with 100 nM TMRE for 30 minutes at 37°C 
and 5% CO2. We used a Live/Dead® Near-IR Dead Cell stain kit from Invitrogen to 
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exclude dead cells. Cells were analyzed via flow cytometry with a DAKO Cyan 
cytometer. The mitochondrial uncoupler FCCP acted as a positive control. 
5.2.7. Confocal microscopy 
C2C12 myotubes were grown in Lab-Tek microscopy chambers (Nunc, NY, USA) and 
treated with simvastatin for 6 h. The cells were fixed with 4% PFA, permeabilized with 
0.2% Triton-X and then labelled with the appropriate antibody. We used DAPI to stain 
nuclei. We used a Zeiss LSM 710 confocal microscope to take the images, and Zen 
software to process them. 
5.2.8. Measurement of oxygen consumption and extracellular acidification rates 
We measured intact cellular respiration with a Seahorse XF24 analyzer (Seahorse 
Biosciences, North Billerica, MA, USA). HepG2 cells and C2C12 myotubes were grown 
in Seahorse XF 24-well cell culture microplates 250 µl growth medium. We treated the 
cells with simvastatin and other relevant compounds for the times indicated, and then 
replaced the medium with 750 µl unbuffered medium. Cells were equilibrated to the 
unbuffered medium for 45 minutes at 37°C in a CO2-free incubator, before being 
transferred to the XF24 analyzer. We measured basal oxygen consumption (OCR) and 
extracellular acidification rates (ECAR), and then sequentially injected 1 µM rotenone, 
10 µM FCCP and 1 µM oligomycin to assess maximal oxidative capacity. 
5.2.9. Isolation of mitochondria 
We seeded 2.7 million C2C12 myoblasts in a T175 flask, and allowed them to 
differentiate. We isolated mitochondria with the technique of Hornig-Do et al. that has 
been commercialised by Miltenyi Biotec (Germany).30  After enrichment, the 
mitochondria were washed and resuspended in Miltenyi storage buffer, and kept on ice 
until use. We measured protein concentration with a BCA kit, and averaged a yield of 
300 µg mitochondrial protein per T175 flask of differentiated myotubes. 
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5.2.10. Immunoblotting 
After treatment, we lysed the cells and collected total cell protein as described 
previously. We separated 15 µg protein on a 4-12% gradient gel (Invitrogen, CA, 
U.S.A.), transferred them to polyvinylidendifluoride membranes, and probed with the 
relevant antibody (all used at a 1:1000 dilution). Peroxidase-labelled anti-rabbit 
antibody, and chemiluninescence substrate (GE Healthcare) were used for analysis. 
5.2.11. Atrogin-1 mRNA expression 
C2C12 myotubes were treated as described. RNA was extracted and purified using the 
Qiagen RNeasy mini extraction kit, with a DNA digest step to ensure pure RNA. We 
synthesized cDNA using the Qiagen omniscript system, and used 10 ng cDNA for 
quantitative RT-PCR. We used SYBR green with primers specific for atrogin-1(forward 
primer: 5’-GAAGACCGCTACTGTGGAA-3’; reverse primer:  
5’-ATCAATCGCTTGCGGATCT-3’). Relative quantities of specifically amplified cDNA 
were calculated with the comparative-threshold cycle method. GAPDH acted as 
endogenous reference (forward primer: 5’-CATGGCCTTCCGTGTTCCTA-3’; reverse 
primer: 5’-CCTGCTTCACCACCTTCTTGA-3’), and no-template and no-reverse-
transcription controls ensured non-specific amplification could be excluded. 
5.2.12. Statistical analysis 
All results are expressed as mean ± SD and evaluated with Student’s t-test, where p 
values of ˂0.05 were considered significant. We performed the calculations using SPSS. 
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5.3. Results 
5.3.1. Mitochondrial membrane potential (ψm) is impaired by simvastatin in 
C2C12 myotubes but not in HepG2 cells 
We previously showed that 10 µM simvastatin is toxic to C2C12 myotubes, but not to 
HepG2 cells. We now determined whether there is a difference in the effects on 
mitochondria. The mitochondrial ψm is a reliable indicator of mitochondrial health, and 
it was not altered in HepG2 cells treated with 10 µM simvastatin for up to 24 h (Fig 1A). 
C2C12 mitochondrial ψm was not reduced after 6 h treatment with 10 µM simvastatin 
(Fig 1B), but had significantly reduced by 11.5% (p=0.04, compared to control) by 24 h 
treatment (Fig 1C). We therefore only treated HepG2 cells for 24 h for the following 
experiments, and used both a 24 h treatment and earlier 6 h treatment to assess toxic 
mechanisms in C2C12 myotubes. 
5.3.2. Simvastatin reduces oxygen consumption in intact C2C12 myotubes, but 
not in HepG2 cells 
To delve deeper into how simvastatin affects C2C12 mitochondria, we used a XF24 
analyzer to determine changes in OCR and ECAR in simvastatin-treated intact C2C12 
myotubes and HepG2 cells. OCRs provided a measurement of the activity of the 
electron transport chain (ETC), and ECARs an indication of the rate of glycolysis. 
Oxygen consumption was unaltered after 24 h treatment with 10 µM simvastatin in 
HepG2 cells (Fig 2A). After only 6 h treatment with 10 µM simvastatin in C2C12 
myotubes, baseline OCR values were already significantly reduced by 24.2% (p=0.00006 
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 compared to control; Fig 2B). The OCR reduction with 10 µM simvastatin was still 
evident after 24 h treatment (data not shown). FCCP was added to the cells to 
determine maximum respiration. The maximum respiration was not reduced in C2C12 
myotubes treated with 10 µM simvastatin for 6 h, or HepG2 cells treated for 24 h. 
5.3.3. Oxygen consumption is also reduced in primary mouse myotubes 
We also determined the OCRs in primary mouse myotubes treated with 10 µM 
simvastatin to confirm our in vitro studies. The primary myotubes showed a similar 
reduction in OCR to the C2C12 myotubes, but only after 24 h treatment (by 25.4%, 
p=0.00001; Fig 2C). This offers further evidence that simvastatin impairs skeletal muscle 
mitochondrial function. 
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Figure 1   
Effect of simvastatin on mitochondrial ψm in HepG2 
cells and C2C12 myotubes. Cells were incubated with 
DMSO or 10 µM simvastatin. A HepG2 cells were 
treated for 24 h. C2C12 myotubes were treated for 6 h 
(B) or 24 h (C). TMRE was used to determine mito-
chondrial membrane potential, and Near-IR dye from 
Invitrogen to exclude dead cells. FCCP was added to 
one of the DMSO samples to act as a positive control. 
The results are means of four independent experi-
ments carried out in triplicate.  
* p < 0.05 and ** p˂0.01 versus control. 
A B 
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5.3.4. Oxygen consumption is also reduced in mitochondria isolated from  
C2C12 myotubes 
We isolated mitochondria from C2C12 myotubes treated with 10 µM simvastatin, to 
fully confirm our results. State II (absence of exogenous ADP), and state III (presence of 
exogenous ADP) respiration was measured on the XF-24 analyzer. No changes in 
respiration were observed using glutamate/malate/pyruvate as substrates (data not 
shown). With succinate as the substrate, both state II and state III respiration were 
significantly reduced in mitochondria isolated from C2C12 myotubes treated with 10 
µM simvastatin for 6 h (by 23.4% p˂0.01 and 22.2% p˂0.01, respectively; Fig 3).  
A B 
C 
Figure 2   
Effect of simvastatin on oxygen consumption in intact HepG2 cells, C2C12 myotubes and isolated 
mouse leg myotubes. Cells were incubated with DMSO (blues lines)or 10 µM simvastatin (red lines). 
The XF24 analyzer was used to take measurements. OCRs are shown for 24 h treatment in HepG2 (A) 
cells, 6 h treatment in C2C12 myotubes (B) and 24 h treatment in isolated mouse leg myotubes (C).  
1 µM oligomycin, 10 µM FCCP and 1 µM rotenone were added at the indicated points. Results are 
indicative of three independent experiments. 
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5.3.6. Inhibiting Akt leads to toxicity and inhibition of the ETC in simvastatin- 
          treated HepG2 cells 
We inhibited Akt in HepG2 cells using the specific inhibitor X from Sigma (5 µM).We 
confirmed inhibition of Akt phosphorylation by immunoblotting (Fig 4A), and also 
showed that Akt remains unphosphorylated when HepG2 cells are treated with 10 µM 
simvastatin and 5 µM  inhibitor X (Fig 4B). Coincubation of 10 µM simvastatin with 5 µM 
inhibitor X also increased the number of apoptotic HepG2 cells (Fig 4C), and reduced 
basal mitochondrial oxygen consumption (Fig 4D). 
5.3.7. Activation of the Igf-1/Akt pathway rescues C2C12 myotubes from 
simvastatin-induced mitochondrial impairment 
It is well recorded that Igf-1 can rescue skeletal muscle from statin-induced damage, so 
we investigated whether Igf-1 could also rescue mitochondrial respiration in C2C12 
myotubes. We used a 24 h treatment time, as there was no change in the number of 
apoptotic cells after 6 h treatment with 10 µM simvastatin. Myotubes treated with10 µM 
simvastatin showed a significant increase in the number of early apoptotic cells when 
compared to DMSO control (by 2.43-fold, p=0.04; Fig 4E). Co-incubation of Igf-1 with 10 
µM simvastatin led to the expected reduction in the number of apoptotic C2C12 
myotubes (reduced 2.72-fold compared to 10 µM simvastatin treatment, p=0.03; Fig 4E).  
Figure 3   
Effect of simvastatin on oxygen con-
sumption in mitochondria isolated from 
C2C12 myotubes. Cells were incubated 
with DMSO (black bars) or 10 µM sim-
vastatin (white bars) for 6 h, mito-
chondria isolated, and the XF24 analyzer 
used to measure oxygen consumption at 
state II and state III. Results are indicative 
of four independent experiments carried 
out in quintuplicate.  
** p < 0.01 versus DMSO control. 
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The influence of Igf-1/Akt signalling on simvastatin-induced mitochondrial toxicity in HepG2 cells and C2C12 myotubes. 
Immunoblots for total and phosphorylated Akt in HepG2 cells treated for 24 h with the indicated drugs (A), and transfected 
C2C12 myotubes treated for 6 h with 10 µM simvastatin (B). Actin was used as a loading control. The results are indicative of 
three independent experiments. C Annexin V/PI analysis of HepG2 cells treated with simvastatin and/or Akt inhibitor X, and 
analyzed by flow cytometry. The bars show the ratio of late apoptotic cells relative to DMSO, and are averages of four 
independent experiments carried out in triplicate. D Comparison of OCRs in HepG2 cells treated with simvastatin and/or Akt 
inhibitor X. The results are the means of four independent experiments carried out in quintuplicate. E Annexin V/PI analysis of 
C2C12 myotubes treated with simvastatin and/or Igf-1, and analyzed by flow cytometry. The bars show the ratio of early 
apoptotic cells relative to DMSO, and are averages of four independent experiments carried out in triplicate. F Comparison of 
OCRs in C2C12 myotubes treated with simvastatin and/or Igf-1. The results are the means of four independent experiments 
carried out in quintuplicate. * p < 0.05 versus DMSO control, and 
ǂ
 p < 0.05 versus 10 µM simvastatin. 
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The coincubation of Igf-1 with 10 µM simvastatin also increased mitochondrial 
respiration in C2C12 myotubes after 24 h treatment (Fig 4F). 
5.3.8. Constitutively active Rap1 also partially rescues C2C12 myotubes from 
simvastatin-induced mitochondrial toxicity 
We decided to further investigate how simvastatin could lead to inhibition of the Igf-
1/Akt pathway, and lead to the reduction in mitochondrial respiration. Previous work 
by Baviera et al. suggests that Rap1 could link cAMP signalling to Igf-1/Akt signalling.25  
Our own lab has also already shown that simvastatin reduces Rap1 
geranylgeranylation.6  We hypothesized that reduction in Rap1 activity could therefore 
lead to a reduction in signalling through the Igf-1/Akt pathway. We therefore 
transiently expressed constitutively active Rap1in C2C12 myotubes (C2C12-Rap1) to 
discover whether it could rescue mitochondrial respiration after treatment with 10 µM 
simvastatin. Mock-transfected (C2C12-mock) and pEGFP-transfected (C2C12-pEGFP) 
myotubes acted as controls. C2C12-mock and C2C12-pEGFP myotubes showed the 
expected decrease in OCR after treatment with 10 µM simvastatin (by 37.1% and 33% 
respectively; Fig 5). C2C12-Rap1 myotubes had partially rescued mitochondrial 
respiration when treated with 10 µM simvastatin for 6 h (a decrease of only 16.1%; Fig 5). 
This suggests that Rap1 could play a role in mitochondrial health, and that its 
dysregulation may be an important stage in simvastatin-induced myotoxicity. 
5.3.9. Constitutively active Rap does not prevent the transcription of atrogin-1 
Dysregulation of the Igf-1/Akt pathway is known to be a key step in the induction of 
atrophy via reduction of Akt phosphorylation, translocation of the Foxo transcription 
factors to the nucleus and transcription of the E3 ubiquitin ligase atrogin-1. Previous 
studies show that atrogin-1 transcription is increased after statin treatment, and that 
atrogin-1 knockout zebrafish are resistant to statin-induced myopathy – offering strong 
evidence that atrogin-1 is a key regulator of statin-induced myopathy. We therefore  
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Figure 5   
The effect of expressing constitutively active Rap1 on 
mitochondrial toxicity in C2C12 myotubes. C2C12-
mock, C2C12-pEGFP and C2C12-Rap1 myotubes were 
treated with DMSO or 10 µM simvastatin for 6 h. OCR 
was measured on a XF24 analyzer. Results are 
indicative of three independent experiments carried 
out in quintuplicate.  
* p < 0.05 versus C2C12-mock. 
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Figure 6   
Effect of expressing constitutively active Rap1 on 
atrogin-1 induction in C2C12 myotubes. A Co-loca-
lization of Foxo1 with nuclei. Results are the mean of 
3 independent experiments. B Co-localization of 
Foxo3a with nuclei. C Atrogin-1 mRNA levels were 
also measured in transfected C2C12 myotubes. The 
results are means of three independent experiments.  
* p < 0.05 versus DMSO control. 
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investigated whether Akt phosphorylation, Foxo nuclear translocation and atrogin-1 
expression are altered in C2C12-Rap1 myotubes.  
C2C12-mock, C2C12-pEGFP and C2C12-Rap1 myotubes all showed reduced levels of 
phosphorylated Akt after simvastatin treatment (Fig 4B). C2C12-mock, C2C12-pEGFP 
and C2C12-Rap1 myotubes showed no increase in Foxo1 nuclear translocation when 
treated with 10 µM simvastatin (Fig 6A). An increase in Foxo3a nuclear translocation was 
observed in 10 µM simvastatin-treated C2C12-mock and C2C12-pEGFP myotubes (Fig 
6B). This increase in Foxo3a nuclear translocation was not observed in C2C12-Rap1 
myotubes treated with 10 µM simvastatin (Fig 6B). 
C2C12-mock and C2C12-pEGFP myotubes treated with 10 µM simvastatin showed the 
expected increase in atrogin-1 transcription (Fig 6C). The reduction in nuclear Foxo3a in 
10 µM simvastatin-treated C2C12-Rap1 myotubes did not lead to a decrease in atrogin-1 
transcription. 
5.4. Discussion 
Statins are widely reported to cause side-effects in skeletal muscle, ranging from mild 
weakness to severe rhabdomyolysis.31–33  There major site of action is the liver, where 
they are well-tolerated and not toxic. We have previously shown differences in 
cholesterol metabolism between liver HepG2 cells and skeletal muscle C2C12 
myotubes.6  Other studies show that statins are mitochondrial toxins, and that reduction 
in mitochondrial respiration may be a contributing factor to skeletal muscle 
myopathy.11,34,35  We have expanded on these studies by showing that simvastatin 
significantly reduces oxygen consumption in C2C12 myotubes, but has no effect on 
oxygen consumption in simvastatin-treated HepG2 cells. This result complements the 
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previous studies, and suggests that mitochondrial health is an important indicator of 
susceptibility to simvastatin in skeletal muscle. 
Numerous signalling pathways are known to be important in maintaining 
mitochondrial health, and statins are also known to dysregulate a wide range of 
signalling pathways such as AMPK, JNK and Igf-1 signalling.36–38  We therefore decided 
to investigate whether differences in cell signalling could explain the difference in 
mitochondrial respiration in simvastatin-treated HepG2 cells and C2C12 myotubes. We 
chose the Igf-1/Akt signalling pathway as it is both well-described to be altered by statin 
treatment in muscle and play a role in mitochondrial maintenance.21–24 
We observed a key difference in phosphorylation state of Akt between the two cell 
lines: Akt was dephosphorylated in simvastatin-treated C2C12 myotubes, whereas 
simvastatin-treated HepG2 cells showed no change in Akt phosphorylation. This is the 
first study to show no change in Akt phosphorylation after simvastatin treatment, 
although a previous study does show reduced Akt phosphorylation in pravastatin-
treated HepG2 cells.39  The decrease in phosphorylated Akt in simvastatin-treated 
C2C12 myotubes complements the results of Hanai et al. that show lovastatin decreases 
phosphorylated Akt in C2C12 myotubes.26  Further weight is added by the study of 
Mallinson et al., who saw similar reductions in Akt phosphorylation in simvastatin-
treated Wistar rats.40 
This difference could reflect a difference in the activity of the Igf-1/Akt signalling 
pathway in the two cell lines, as Akt phosphorylation is essential to its activity, and 
points to a potential explanation to why simvastatin is toxic to C2C12 myotubes but not 
to HepG2 cells: simvastatin-induced toxicity is dependent on Akt maintaining 
mitochondrial function 
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To test our theory, we inhibited Akt activity in HepG2 cells, and activated Akt in C2C12 
myotubes. Coincubation of simvastatin with Akt inhibitor X in HepG2 cells led to a 
lowering of mitochondrial respiration and cell viability. This suggests that the ability of 
HepG2 cells to increase Akt phosphorylation upon simvastatin-treatment is one 
mechanism by which they are protected from toxicity. It also points to the maintenance 
of mitochondrial respiration playing an important role in protecting HepG2 cells after 
simvastatin-treatment. Coincubation of C2C12 myotubes with simvastatin and Igf-1 had 
the expected effect of rescuing the cells from apoptosis, and also reinstated 
mitochondrial respiration. This confirms the previous studies describing the importance 
of Igf-1/Akt signalling in statin-induced myotoxicity, and adds to this knowledge by 
showing that Igf-1/Akt signalling can rescue mitochondrial function in simvastatin-
treated cells.12,26  Although we did not perform activity assays on the complexes of the 
mitochondrial respiratory chain, the fact that Igf-1 rescued mitochondrial respiration in 
C2C12 myotubes implies that direct inhibition of the complexes may not be a relevant 
concern. 
It is so far unknown how statins can reduce Igf-1/Akt signalling and lead to toxicity. 
Previous work, including studies from our own lab, show that statins can decrease the 
production of various intermediates in the cholesterol production pathway.4–6  These 
intermediates, such as ubiquinone, geranylgeranyl pyrophosphate (GGPP) and 
dolichol, are important in a wide-range of cellular processes.41–43  GGPP is important for 
the geranylgeranylation of proteins, and many geranylgeranylated proteins are 
required for cell signalling. Our previous work shows that Rap1, a small GTPase, has 
reduced geranylgeranylation after simvastatin treatment in C2C12 myotubes.6  Other 
groups show Rap1 potentiates Igf-1 signalling, and Baviera et al. have postulated that 
Rap1 links cAMP signalling to Igf-1/Akt signalling.25  On this evidence, we queried 
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whether it is the disruption of Rap1 in C2C12 myotubes that leads to a dysregulation of 
mitochondrial respiration after simvastatin-treatment. 
We transfected constitutively active Rap 1 into C2C12 myotubes (C2C12-Rap1), and 
witnessed a partial rescue of mitochondrial respiration after simvastatin treatment 
compared to C2C12-mock and C2C12-pEGFP myotubes. This implies that Rap1 activity 
is important in maintaining mitochondrial function. This complements previous work 
by Qiao et al. showing that Epac, an activator of Rap1, is partially located in the 
mitochondria.44  Others also show Rap1 can be found in mitochondria.45,46  cAMP is also 
located in mitochondria, and thought to regulate mitochondrial function.47,48  Our data 
adds to this knowledge by offering further evidence of the importance of Rap1 to 
mitochondrial health. Our data also provides evidence that simvastatin exerts its 
deleterious effects on C2C12 myotube mitochondria via impairment of Rap1. 
Our results do not, however, point to Rap1 activating the Igf-1/Akt pathway. Although 
we saw a decrease in nuclear Foxo3a, we saw no increase in Akt phosphorylation or 
decrease in atrogin-1 transcription in simvastatin-treated C2C12-Rap1 when compared 
to C2C12-mock or C2C12-pEGFP myotubes. This suggests that Rap1 protects the 
mitochondria via a non-Igf-1/Akt mechanism. When taken with our data showing that 
Igf-1 can rescue simvastatin-induced mitochondrial impairment, our results point to 
multiple pathways having a role in both inducing, and protecting from, toxicity. 
How simvastatin can impair the Igf-1/Akt pathway is still unknown, but Rap1 may still 
be a key player. It may be that the level of constitutively active Rap1 was not high 
enough to activate the pathway. Our transfection efficiency was only 30%, which may 
be high enough to rescue mitochondrial respiration but not rescue Akt signalling. We 
aim to further investigate the role of Rap1 in the Igf-1/Akt signalling pathway by 
increasing this efficiency. 
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Our data has, for the first time, provided an explanation for the difference in 
susceptibility to toxicity between liver HepG2 cells and skeletal muscle C2C12 
myotubes. The effect of statins on Akt phosphorylation are well-reported, but this is the 
first study providing evidence for differing Akt phosphorylation states predisposing 
cells to simvastatin-induced toxicity. Also, although preliminary, the ability of Rap1 to 
restore mitochondrial respiration in C2C12 myotubes provides an important link 
between cellular metabolism and signalling, and a potential partial explanation for 
simvastatin-induced toxicity. 
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6.  Abstract 
Aims:  Statins are widely used to prevent cardiovascular diseases. They are well-tolerated, with 
adverse reactions mainly seen in skeletal muscle. We studied whether they also have adverse 
effects in cardiomyocytes.  Methods and results:  We treated Wistar rats, isolated rat 
cardiomyocytes and H9C2 cells with simvastatin to thoroughly investigate any toxic effects. We 
assayed for signs of apoptosis, mitochondrial dysfunction and cellular atrophy. Lighter hearts 
were observed in simvastatin-treated rats (80 mg/kg/day for 13 days). Both isolated 
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cardiomyocytes and H9C2 cells showed toxicity and reduction in mitochondrial oxygen 
consumption after exposure to 10 µM simvastatin. The mitochondrial membrane potential was 
also compromised in the H9C2 cells. Signs of atrophy – Foxo3a nuclear translocation and 
atrogin-1 transcription – were increased in H9C2 cardiomyocytes.  Conclusion:  Simvastatin 
reduces heart weight in Wistar rats and us toxic to rat cardiomyocytes  and H9C2 cells. This 
could be explained by compromised mitochondrial function and induction of atrophy by 
increased expression of atrogin-1. Further work is required to discover if this is also the case in 
humans. 
6.1.  Introduction 
Statins are among the most prescribed drugs in Western countries. They reduce 
morbidity and mortality from coronary heart disease (CHD) and mitigate the risk of 
stroke.1,2 Their major site of action is the liver, where they inhibit HMG-CoA (hydroxyl-
methyl-glutaryl-coenzyme A) reductase, the rate-limiting step in cholesterol 
biosynthesis. Inhibition of this pathway also impairs other processes, such as 
ubiquinone production and the isoprenylation and N-linked glycosylation of proteins.3  
Altering these processes can reduce inflammation, oxidative stress and platelet 
adhesion.4  This helps prevention of, and recovery from, CHD, the major cause of death 
in industrialized countries.5  
Statins are generally well tolerated but there are dose-dependent adverse reactions, 
particularly in skeletal muscle where myopathy is seen in 1–5% of patients.6,7  These 
adverse reactions are also thought to be linked to the pleiotropic effects of statins. We 
have demonstrated previously that a reduction in geranylgeranylation and N-linked 
glycosylation in C2C12 myotubes could be the cause of myotoxicity.8  
Adverse reactions of statins in cardiac muscle have been much less studied, but could 
be of great clinical relevance. To our knowledge there are only a few previous papers on 
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the subject, which show that lovastatin reduces cardiomyocyte viability, in part via an 
increase in apoptotic pathways.9,10  Studies in other tissues show statins can affect the 
mitochondria directly, via inhibition of the complexes of the respiratory chain, or 
indirectly via lowering of ubiquinone levels.11,12  Previous work in our lab showed that 
statins can alter mitochondrial function in skeletal muscle, but no studies have so far 
addressed how statins affect cardiac mitochondria.13  Statins are also known to increase 
levels of the atrophy-inducing protein atrogin-1 in skeletal muscle.14  This increase in 
atrogin-1 levels is thought to be a contributing factor in statin-induced skeletal muscle 
toxicity. Previous studies show atrogin-1 is present in cardiac muscle, and is 
upregulated during experimental heart failure.15,16  Whether this occurs in statin-treated 
cardiomyocytes has not been addressed. 
We aimed to investigate how simvastatin affects cardiomyocyte mitochondria and the 
atrophy pathway. Male Wistar rats provided a model to observe any initial adverse 
effects of simvastatin on the heart in vivo. We then used isolated primary rat 
cardiomyocytes ex vivo, and the rat cardiomyocyte cell line H9C2, which is a well-
established in vitro model for cardiac cell studies, for a more in-depth analysis.  
 This is the first study elucidating how simvastatin adversely affects cardiomyocytes 
and induces signs of atrophy. It allows both a deeper understanding of the pleiotropic 
effects of statins in cardiomyocytes and the risk they might pose to cardiovascular 
patients.  
6.2.  Materials and methods 
6.2.1. Chemicals 
Simvastatin (Sigma-Aldrich, St. Louis, MO, USA) was converted into the active acid 
following the protocol of Bogman et al.17  Stock solutions of 10 and 100 mM simvastatin 
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in DMSO were stored at –20°C. The ToxiLight® assay kit LT07-117 was from Lonza 
(Basel, Switzerland) and the Pierce BCA protein assay kit from Merck (Darmstadt, 
Germany). Antibodies to Foxo1 and Foxo3a were provided by Cell Signaling 
Technology (Danvers, MA, USA). The Alexa Fluor® secondary antibodies were from 
Invitrogen (Basel, Switzerland). All other chemicals were supplied by Sigma-Aldrich 
(St. Louis, MO, USA), except where indicated. 
5.2.2. Animals 
Male Wistar rats (8-weeks old) were divided into two groups: control and simvastatin-
treated. We dissolved simvastatin in water and intragastrically administered 80 mg/kg 
body weight/day for 13 days. Control animals received an equivalent amount of water. 
The rats were killed after 14 days, and hearts harvested according to the ‘Ethical 
Principles in Animal Research’ adopted by the Brazilian College of Animal 
Experimentation (COBEA). The experiments were approved by the Ethical Commission 
of Ethics in Animal Research (157/2008), School of Medicine of Ribeirão, University of 
São Paulo, Brazil. 
6.2.3. Isolation of neonatal rat cardiomyocytes 
We isolated neonatal rat ventricular myocytes (NRVMs) from Wistar rats using a 
protocol modified from Bursac et al.18  Briefly, we digested the hearts with sequential 
collagenase incubations. We plated the cells for an hour, allowing non-myocytes to 
adhere to the plate, and collected the enriched suspension of myocytes. Myocytes were 
seeded at a density of 100,000 cells/cm2 and 100 µM bromodeoxyuridine (BrdU) added 
to prevent non-myocyte proliferation. 
6.2.4. Cell culture 
H9C2 cardiomyocytes were provided by Dr Pfister (University Hospital Basel, 
Switzerland), and grown in Dulbecco modified Eagle’s medium (DMEM) high-glucose 
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medium (4.5 g/l) containing GlutaMAXTM-1 (Gibco 61965), supplemented with 10% FBS, 
5 mM HEPES, 1 mM sodium pyruvate and 500 µg/ml penicillin-streptomycin. Myoblasts 
were seeded at 150,000 cells/well of a 6-well plate (or equivalent), and grown for 2 days 
before drug treatment. We added simvastatin at a concentration of 10 and 100 µM. 
DMSO was used as a control; its concentration was 0.1%. Cells were grown in a 
humidified incubator with 5% CO2 at 37°C. 
6.2.5. Cytotoxicity assay 
The loss of cell membrane integrity results in the release of adenylate kinase (AK), 
which can be quantified by the ToxiLight assay kit. After incubation with simvastatin 
for 6 and 24 h, we used the protocol outlined in Mullen et al.8 
6.2.6. Detection of apoptosis after simvastatin treatment 
We used an in situ apoptosis detection kit for Annexin V binding and propidium iodide 
(PI) staining (VybrantTM Apoptosis Assay Kit #2, from Invitrogen). After 24 h incubation 
with simvastatin, we stained detached cells with 5 µl Annexin V-AlexaFluor 488 and 1 
µl PI (final concentration 1 µg/ml) in Annexin V buffer as per the kit protocol. The 
samples were incubated for 15 minutes and analysed using a DAKO Cyan cytometer. 
6.2.7. Measurement of mitochondrial membrane potential 
We used tetramethylrhodamine ethyl ester (TMRE) to detect changes in mitochondrial 
membrane potential (ψm).19  Cells were incubated with simvastatin for 24 h, then 
detached and incubated with 100 nM TMRE for 30 minutes at 37°C and 5% CO2. We 
used a Live/Dead® Near-IR Dead Cell stain kit from Invitrogen to exclude dead cells. 
Cells were analyzed with a DAKO Cyan cytometer. The mitochondrial uncoupler FCCP 
acted as a positive control. 
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6.2.8. Confocal microscopy 
H9C2 cardiomyocytes were grown in Lab-Tek microscopy chambers (Nunc, NY, USA) 
and treated with simvastatin for 24 h. The cells were fixed with 4% PFA, permeabilized 
with 0.2% triton-X and then labelled with the appropriate antibody. We used DAPI to 
stain nuclei. We used a Zeiss LSM 710 confocal microscope to take the images, and Zen 
software to process them (Carl Zeiss, Switzerland). 
6.2.9. Measurement of oxygen consumption and extracellular acidification rates 
We measured intact cellular respiration with a Seahorse XF24 analyzer (Seahorse 
Biosciences, North Billerica, MA, USA). H9C2 cells were seeded in Seahorse XF 24-well 
cell culture microplates at 5000 cells per well in 250 µl growth medium. We treated the 
cells with simvastatin for 24 h, and then replaced the medium with 750 µl unbuffered 
medium. Cells were equilibrated to the unbuffered medium for 45 minutes at 37°C in a 
CO2-free incubator, then transferred to the XF24 analyzer. We measured basal oxygen 
consumption (OCR) and extracellular acidification rates (ECAR), and then sequentially 
injected 1 µM rotenone, 15 µM FCCP and 1 µM oligomycin to assess maximal oxidative 
capacity. 
6.2.10. Measurement of reactive oxygen species 
We used a fluorescent-based microplate assay to evaluate the oxidative stress in 
simvastatin-treated H9C2 cardiomyocytes. The cardiomyocytes were co-incubated with 
DCFH-DA. DCFH-DA is hydrolysed in the cytoplasm by intracellular esterases to the 
non-fluorescent DCFH, which can be oxidized in the presence of reactive oxygen 
species (ROS) to the fluorescent (DCF). We measured fluorescence, at an excitation 
wavelength of 490 nm and an emission wavelength of 535 nm, with a HTS 700 Plus Bio 
Assay reader (Perkin Elmer, Switzerland). 
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6.2.11. Atrogin-1 mRNA expression 
We treated H9C2 cardiomyocytes with simvastatin for 24 h. RNA was extracted and 
purified using the Qiagen RNeasy mini extraction kit, with a DNA digest step to ensure 
pure RNA. We synthesized cDNA using the Qiagen omniscript system, and used 10 ng 
cDNA for quantitative RT-PCR. We used SYBR green with primers specific for atrogin-
1(forward primer: 5’-GAAGACCGCTACTGTGGAA-3’; reverse primer: 5’-
ATCAATCGCTTGCGGATCT-3’). Relative quantities of specifically amplified cDNA 
were calculated with the comparative-threshold cycle method. GAPDH acted as 
endogenous reference (forward primer: 5’-CATGGCCTTCCGTGTTCCTA-3’; reverse 
primer: 5’-CCTGCTTCACCACCTTCTTGA-3’), and no-template and no-reverse-
transcription controls ensured non-specific amplification could be excluded. 
6.2.12. Statistical analysis 
All results are expressed as mean ± SD and evaluated with Student’s t-test, where p 
values of ˂0.05 were considered significant. We performed the calculations using SPSS. 
6.3. Results 
6.3.1. Simvastatin reduces growth and heart weight in Wistar rats 
We treated Wistar rats with 80 mg/kg/day simvastatin for 13 days so that we could 
observe any effects of the drug on heart size and weight. Animals were sacrificed on 
day 14. The overall growth rate was significantly reduced after 7 days in the treated 
animals compared to control rats (Fig 1A). The simvastatin-treated rats also had 
significantly lighter hearts (a reduction of 21% compared to control, p˂0.05; Fig 1B). The 
ratio of heart weight to body weight was also reduced at the end of the study (from 
0.33% in control rats to 0.29% in treated rats), indicating that the reduced heart weight 
was not due to a generic reduction throughout the body. This suggested that  
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simvastatin is associated with cardiac atrophy, and led us to investigate the toxicity and 
induction of atrophy in ex vivo and in vitro models. 
6.3.2. Simvastatin induces cytotoxicity in primary NRVMs and H9C2 
       cardiomyocytes 
We treated isolated NRVMs with simvastatin to discover if simvastatin is directly toxic 
to cardiomyocytes. We measured the release of AK from cells to determine the 
cytotoxicity. NRVMs showed significant toxicity with 10 µM simvastatin (an increase of 
1.43 fold compared to control, p˂0.05; Fig 2A). The rat cell line H9C2 then provided an in 
vitro model to further investigate whether simvastatin could be toxic to cardiomyocytes. 
We used a range of concentrations from 0.1 to 100 µM simvastatin (Fig 2B). We observed  
Figure 1   
Effect of simvastatin on growth rate and 
cardiac atrophy in Wistar rats. Male 
Wistar rats received water (blue line) or 
simvastatin (80 mg/kg/day, s.c.; red line) 
for 13 days. A Body weight was measured 
each day. B Heart weight was measured 
for rats treated with water or simva-
statin. Each data point represents the 
mean of 8 or 9 muscles.  
* p < 0.05 in relation to control group. A 
B 
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no significant toxicity with 0.1 or 1 µM at any timepoint. 10 µM was the lowest 
concentration that led to cell death of H9C2 cardiomyocytes after 24 h – they had a 
significant increase in AK release of 1.28 fold compared to control cells. 100 µM was 
already toxic at 6 h. These results allowed us to consider H9C2 cardiomyocytes a 
suitable model for simvastatin-induced cardiomyocyte toxicity. We used 24 h treatment 
with 10 and 100 µM simvastatin for the remaining experiments. 
6.3.3. Apoptosis is the major form of cell death 
We used Annexin V/PI staining to measure the type of cell death seen in H9C2 
cardiomyocytes treated with simvastatin for 24 h. H9C2 cardiomyocytes treated with 10 
µM simvastatin showed a significant increase in early apoptotic cells when compared to 
control (6.33 versus 2.97%; Fig 3). This increase was concentration dependent – 
treatment with 100 µM simvastatin showed a larger increase in early apoptotic cells  
Figure 2   
Toxicity of simvastatin on cardio-
myocytes. A Isolated primary rat cardio-
myocytes were treated with DMSO or 10 
µM simvastatin for 6 h, 24 h or 48 h.  
B H9C2 cardiomyocytes were incubated 
for 6 h (white bars), 24 h (grey bars) or  
48 h (black bars) with the simvastatin 
concentrations indicated. We measured 
the release of AK into the medium. 
DMSO-treated cells were used as a 
control. Results are expressed as ratios to 
the DMSO control. Each bar represents 
the mean of five independent exper-
iments carried out in duplicate.  
* p < 0.05 and ** p < 0.01, versus control. 
A 
B 
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(9.18%; Fig 3). An increase in the late apoptotic fraction was only seen in cells treated 
with 100 µM simvastatin (18.21 versus 11.58%; Fig 3). 
6.3.4. Mitochondrial ψm is reduced 
Previous work by our lab and others points to statins impairing the mitochondria in 
other cell types. To see if this was the case in cardiomyocytes, we assayed for changes in 
the mitochondrial ψm with the dye TMRE. TMRE localization to mitochondria is 
dependent upon the mitochondrial ψm – a reduction in mitochondrial ψm leads to a 
reduction in the fluorescent signal.19  A compromised mitochondrial ψm is an indicator 
of impaired mitochondrial function. We pre-treated the cells for 24 h with DMSO, 10 µM 
and 100 µM simvastatin (Fig 4). H9C2 mitochondrial membrane potential was 
significantly reduced after treatment with both 10 µM and 100 µM simvastatin (by 18.4 
and 34.7%, respectively). The positive control, FCCP, showed the expected reduction in 
mitochondrial membrane potential (by 78.2%). 
Figure 3   Annexin V/PI analysis after simvastatin treatment. Cells were 
incubated with DMSO, 10 µM or 100 µM simvastatin for 24 h. 
The cells were then labelled with Annexin V and PI, and 
analysed via flow cytometry. Early (white bars) and late (black 
bars) apoptotic cells were quantified. The data represents the 
mean of four experiments carried out in triplicate.  
* p < 0.05 and ** p < 0.01, versus control. 
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6.3.5. Simvastatin reduces oxygen consumption in intact H9C2 myocytes 
To delve deeper into how simvastatin affects H9C2 mitochondria, we used a XF24 
analyzer to determine changes in OCR and ECAR in simvastatin-treated intact H9C2 
cardiomyocytes. OCRs provided a measurement of the activity of the electron transport 
chain (ETC), and ECARs an indication of the rate of glycolysis. DMSO-treated control 
cells showed very low ECAR values, suggesting that H9C2 cardiomyocytes do not rely 
on glycolysis for energy. OCR rates suggested a functional ETC in control cells. After 6 
h treatment with 10 µM simvastatin, baseline OCR values were already significantly 
reduced by 16% (Fig 5A). The OCR reduction with 10 µM simvastatin was time 
dependent, with a larger drop of 50% observed after 24 h treatment (Fig 5B). FCCP was 
added to the cells to determine maximum respiration. The maximum respiration was 
lower in simvastatin-treated cells at both timepoints (reductions of 9% at 6 h, and 47% 
at 24 h). We saw no change in ECAR values after 6 h treatment with 10 µM simvastatin 
(Fig 5C). ECAR values did, however, drop significantly by 51 % after 24 h treatment with 
10 µM simvastatin (Fig 5D). Treatment for only 6 h with 100 µM simvastatin resulted in a 
complete abolition of oxygen consumption and extracellular acidification, suggesting a  
Figure 4   
Effect of simvastatin on mitochondrial 
membrane potential in H9C2 
cardiomyocytes. Cells were incubated 
with DMSO, 10 µM or 100 µM 
simvastatin for 24 h. TMRE was used to 
determine mitochondrial membrane 
potential, and Near-IR dye from 
Invitrogen to exclude dead cells. FCCP 
was added to one of the DMSO 
samples to act as a positive control. 
The results are means of four 
independent experiments carried out 
in triplicate. * p < 0.05 and ** p < 0.01, 
versus control. 
  
Page 63 
 
  
 
 
 
 
complete inhibition of the ETC and glycolysis at this concentration (Fig 5A and 5C). 
Mitochondrial mass did not change after treatment (data not shown). 
6.3.6. Oxygen consumption is also reduced in primary cardiomyocytes 
We also determined the OCRs in primary cardiomyocytes treated with 10 µM 
simvastatin to confirm our in vitro studies. The primary cardiomyocytes also showed a 
reduction in OCR (of 18%), offering further evidence that simvastatin impairs cardiac 
mitochondrial function (Fig 6A). Baseline ECAR was also reduced by 18% (Fig 6B). 
 
 
Figure 5   
Effect of simvastatin on oxygen consumption and extracellular acidification in 
intact H9C2 cardiomyocytes. Cells were incubated with DMSO (red lines), 10 µM 
(blue lines) or 100 µM (black lines) simvastatin. The XF24 analyzer was used to 
take measurements. OCRs are shown for 6 h (A) and 24 h (B) incubation. ECARs 
are shown for 6 h (C) and 24 h (D) incubation. 1 µM oligomycin, 15 µM FCCP and 
1 µM rotenone were added at the indicated points. Results are indicative of three 
independent experiments. 
A B 
C D 
  
Page 64 
 
  
 
 
6.3.7. ROS levels are not altered by simvastatin 
We measured the ROS levels to investigate whether the decrease in OCR is associated 
with an increase in ROS production. ROS levels in H9C2 cardiomyocytes did not 
change after 24 h treatment with 10 µM simvastatin (Fig 7). Benzbromarone acted as a 
positive control, and showed the expected increase in ROS levels.20 
6.3.8. Simvastatin also leads to Foxo nuclear translocation and transcription of    
          atrogin-1 
The decrease in heart weight in the simvastatin-treated Wistar rats suggested that 
atrophy could be induced by simvastatin. One inducer of atrophy, atrogin-1, is thought 
Figure 6   
Effect of simvastatin on oxygen 
consumption in isolated primary rat 
cardiomyocytes. Cells were incubated 
with DMSO (red line) or 10 µM 
simvastatin (blue line) for 24 h. The 
XF24 analyzer was used to take 
measurements of (A) OCR and (B) 
ECAR. Results are indicative of three 
independent experiments. 
A 
B 
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 to play a key role in statin-induced skeletal muscle myopathy, and its transcription is 
controlled by the Foxo transcription factors. We therefore assayed for induction of 
atrogin-1 in the H9C2 cardiomyocytes. Using confocal microscopy, we observed no 
change in the location of Foxo1 (Fig 8A). Nuclear translocation of Foxo3a was, however, 
increased after 24 h treatment with simvastatin (2.82-fold, p˂0.05; Fig 8A). Consequently, 
atrogin-1 mRNA levels were increased by 1.43 fold after 24 h simvastatin treatment 
(p˂0.05; Fig 8B). 
Figure 7   
ROS levels in simvastatin-treated H9C2 
cardiomyocytes. We incubated the cells 
with DMSO or 10 µM simvastatin for 24 h. 
We used 100 µM benzbromarone as a 
positive control.  Results are shown as 
relative to DMSO-treated control cells. The 
results represent the mean of three 
independent experiments carried out in 
triplicate. 
A B 
Figure 8   Simvastatin-induced atrogin-1 upregulation in H9C2 cardiomyocytes. The cardiomyocytes were 
incubated with DMSO or 10 µM simvastatin for 24 h. A We used confocal microscopy to quantify the 
number of nuclei positive for FoxO1 and FoxO3a. Results are expressed as ratios to DMSO, and 
represent three independent experiments carried out in triplicate. B Atrogin-1 mRNA levels in 10 µM 
simvastatin-treated cells relative to DMSO control. The results are means of three independent 
experiments carried out in triplicate. ** p < 0.01 versus control. 
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6.4.  Discussion 
The myopathic side-effects of statins are frequently reported in skeletal muscle, 
however, little is currently known of their effects on cardiac muscle.21,22  Statins affect a 
multitude of processes, so investigation into whether they have toxic effects in cardiac 
muscle is warranted. This is particularly important as statins are often prescribed to 
patients with cardiovascular disease, so cardiac side-effects may be masked by falsely 
attributing them to the underlying disease.  
We observed that simvastatin-treated rats had hearts of lower weight than controls, 
which pointed to a possible toxic effect associated with cardiac atrophy. We used ex vivo 
and in vitro models to test this hypothesis, with particular focus on how simvastatin 
affects cardiomyocyte death and atrophy pathways. We discovered that 10 µM 
simvastatin has a significant toxic effect in both primary NRVMs and H9C2 
cardiomyocytes after 24 h incubation. The 10 µM concentration of simvastatin that we 
used is higher than would be expected in the plasma of patients, where values do not 
exceed 1 µM. However, localized concentrations could be higher than the observed 
plasma levels, especially when combined with inhibitors of cytochrome P450 or 
OATP1B1.23 
Simvastatin is known to cause apoptosis in a variety of cell types.24– 27  We have added 
to this knowledge by showing that apoptosis also occurs in H9C2 cardiomyocytes 
treated with 10 µM simvastatin. This novel finding led us to further investigate signs 
and mechanisms of apoptosis. We initially observed a decrease in the mitochondrial 
ψm. ψm is an indicator of mitochondrial function, so its decrease points to statins 
having an effect on this organelle. We believe that this change is not a direct result of 
cholesterol lowering, as we and others show in other systems that the cholesterol 
precursor squalene does not reverse the effects of statins in other systems.8,28  This 
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hypothesis is given more credence by studies showing statins inhibit mitochondrial 
function – either through direct inhibition of complexes of the electron transport chain 
or indirectly by reducing ubiquinone levels.11,12  To investigate whether this was the case 
in H9C2 cardiomyocytes, we comprehensively assayed for changes in oxygen 
consumption in both intact primary NRVMs and H9C2 cells. We used a new technique 
to achieve this: the XF24 analyzer to measure OCR and ECAR. OCR indicates activity of 
the mitochondrial ETC, and ECAR the level of glycolysis. A major observation was that 
oxygen consumption was significantly reduced in intact cardiomyocytes after 6 h 
treatment with 10 µM simvastatin (a pre-toxic timepoint). This suggests that changes in 
the mitochondria are a cause, rather than a consequence, of simvastatin-induced toxicity 
in H9C2 cardiomyocytes. This complements work in other cell lines, and is the first time 
a direct effect on oxygen consumption in mitochondria has been seen in a cardiac cell 
line.13,29,30  We confirmed this data in the isolated NRVMs, adding further credence to 
our hypothesis that mitochondria are impaired in cardiomyocytes. Maximum 
respiration was also reduced after simvastatin treatment, again suggesting an 
impairment in the electron transport chain. Only one previous study, in the liver, shows 
statins inhibit glycolysis.31  We have expanded on this observation, by showing a 
reduction in ECAR values in the H9C2 cardiomyocytes, suggesting an inhibition of 
glycolysis. The cells are therefore unable to use glycolysis to compensate for the loss of 
mitochondrial energy production. Inhibition of both mitochondrial function and 
glycolysis explains the susceptibility of cardiomyocytes.  
It is important to discern the mechanism by which simvastatin lowers oxygen 
consumption in cardiomyocytes. This decrease cannot be explained by a reduction in 
mitochondrial mass (we saw no change) or a reduction in ROS production (also 
unaltered, contradicting one of the perceived benefits of statin treatment in 
cardiovascular disease). Statin-induced reductions in oxidative stress occur in other 
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cells, such as erythrocytes and vascular smooth muscle cells.32,33  Previous studies 
suggest that in skeletal muscle, simvastatin inhibits the complexes of the electron 
transport chain, but further work is required to determine whether this also occurs in 
cardiac muscle.13 
Our work also uncovered a second major effect of simvastatin on cardiomyocytes: the 
induction of signs of atrophy. Our initial observation of the lighter atrophic heart was 
reinforced by our in vitro data. The statin-induced upregulation of atrogin-1 production 
is well-studied in skeletal muscle, and known to be controlled by Igf-1/Akt/Foxo 
signalling.34,35  Atrogin-1 is hypothesized to be a major contributing factor to statin-
induced skeletal muscle myopathy.14,36  Our study is the first to show that simvastatin 
induces atrogin-1 in cardiomyocytes. This observation could have great impact on two 
fronts. (1) Positive: the atrophy-inducing effects of simvastatin may account for some of 
its cardiovascular benefits – they could counterbalance the tendency towards 
hypertrophic heart in some patients,37,38  and (2) negative: statin-associated cardiac 
atrophy could negatively impact cardiac contractility, which may be relevant in patients 
with pre-existing heart disease.  
Although preliminary, our data show for the first time that simvastatin adversely alters 
mitochondrial function and induces signs of atrophy in cardiomyocytes. Since 
mitochondrial damage and increased atrogin-1 expression are associated with 
apoptosis, cardiac atrophy can be explained by either event. The precise toxic 
mechanisms remain to be uncovered, so further work is required to fully determine any 
detrimental effects of statins on cardiac tissue. Furthermore, it is important to perform 
similar studies in cardiac tissue obtained from statin-treated humans. 
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Final discussion 
 
STATINS COMPETITIVELY inhibit HMG-CoA reductase, the rate limiting enzyme in 
cholesterol biosynthesis.16  Although they exert their effects primarily in the liver, where 
they are well-tolerated and not toxic, the majority of their side-effects occur in skeletal 
muscle.35–38  These side-effects range from mild muscle ache to potentially fatal 
rhabdomyolysis. It is of paramount importance to uncover the cause(s) of these side-
effects for three reasons: 
1. The increasingly elderly and obese population in the Western world suggests 
that the use of statins will increase year on year, meaning side-effects will be 
more and more relevant. 
2. Side-effects decrease compliance, impacting negatively on the benefit of 
prescribed statins. 
3. Statins have a vast number of pleiotropic effects and uses, from treating cancer to 
Alzheimer’s disease, and therefore a better understanding of side-effects would 
lead to better care. 
7.1.  Comparing cholesterol metabolism in C2C12 myotubes and HepG2   
       cells highlights differences in responses to simvastatin 
The first aim of this thesis is therefore to uncover possible mechanisms behind statin-
induced side-effects in skeletal muscle. We initially chose an in vitro mouse skeletal 
muscle model, C2C12 myotubes, to represent a system that is susceptible to statin-
induced myopathy. We compared responses in this cell line to those in the human 
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hepatic HepG2 cell line, with the aim of uncovering differences between the two that 
might point to why statins are toxic in skeletal muscle but not in the liver. 
The first responses that we compared were direct effects on cholesterol metabolism. We 
thoroughly measured changes not only in cholesterol content and production, but also 
those in ubiquinone production, farnesylation and geranylgeranylation of small 
GTPases, and the rate of N-linked glycosylation. We found that simvastatin was toxic to 
C2C12 myotubes before there was any change in cellular cholesterol ubiquinone 
content, suggesting that toxicity is not related to these two factors. When we 
investigated how simvastatin affects the mitochondrial ETC, we saw that oxygen 
consumption was reduced after treatment, despite there being no change in ubiquinone 
content. This reduction occurred at a pre-toxic timepoint, and is therefore a potential 
candidate for a cause of the toxicity. 
Interestingly, ubiquinone content was reduced in the HepG2 cells, but toxicity was not 
observed. The reduction in ubiquinone levels in the HepG2 cells did not lead to a 
reduction in mitochondrial oxygen consumption, raising the possibility that the ETC in 
HepG2 cells can still function with a reduced ubiquinone content. A study by 
Tavintharan et al. shows a larger decrease in HepG2 ubiquinone content, and that this 
reduction is associated with statin-induced toxicity.180  This suggests that there is a 
critical amount of ubiquinone that HepG2 cells can compensate for. 
When comparing farnesylation and geranylgeranylation, we observed an increase in the 
amount of unfarnesylated Ras and ungeranylgeranylated Rap1 in both the C2C12 
myotubes and the HepG2 cells. At first glance, this would seem to suggest that 
disruption of these processes would therefore not lead to toxicity, but addition of 
geranylgeraniol completely rescued the C2C12 myotubes from simvastatin-induced 
toxicity. This rescue is in line with previous work, and shows the importance that 
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geranylgeranylated proteins play in maintaining cell viability.68,74,115  The addition of 
farnesol did not rescue the C2C12 myotubes to the same extent, suggesting that 
farnseylated proteins, on their own, are not integral in leading to the observed toxicity. 
We saw a difference between the cell lines in the rate of N-linked glycosylation. 
Simvastatin-treated C2C12 myotubes showed a reduction in N-linked glycosylation 
whereas HepG2 cells did not. This offers the possibility that alterations in N-
glycosylated proteins could be a cause of the toxicity seen in the C2C12 myotubes. 
Previous studies implicate statins in incorrect processing of the Igf-1r, and our study 
also hints at this possibility.80,82,83  It is important to point out that the addition of 
farnesol did not rescue the C2C12 myotubes from simvastatin-induced toxicity. 
Farnesol is essential in the formation of dolichol, and the lack of rescue with farnesol 
points to N-glycosylated proteins not having too prominent a role in leading to toxicity. 
7.2.  Igf-1/Akt signalling determines the response to simvastatin in  
       C2C12 myotubes and HepG2 cells 
The Igf-1/Akt pathway has been implicated in the progression of statin-mediated 
toxicity, and we investigated whether this was true with the C2C12 myotubes. The 
pathway was down-regulated at a pre-toxic timepoint, as shown by reduced 
phosphorylation of Akt, increased nuclear Foxo3a, and an upregulation of atrogin-1 
transcription. How statins can disrupt this pathway is still unknown, and we used our 
knowledge from fully characterizing the mevalonate pathway to guide us. 
Previous work by Baviera et al. shows a possible link between cAMP/EPAC signalling 
and the Igf-1/Akt pathway, and that the small GTPase Rap1 could be the link.147  They 
showed that increasing cAMP levels using IBMX, a cAMP-PDE inhibitor, increases Akt 
phosphorylation and rescues dexamethasone-induced upregulation of atrogin-1. We 
postulated that the increase in ungeranylgeranylated Rap1 caused by simvastatin 
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would remove the link between cAMP/EPAC and Igf-1/Akt signalling. To add weight 
to our hypothesis, we noted that Akt signalling was not altered in HepG2 cells. 
Expressing constitutively active Rap1 in the C2C12 myotubes did not, however, reverse 
the simvastatin-induced decrease in Akt phosphorylation or prevent atrogin-1 
transcription. Constitutively active Rap1 did, however, partially rescue mitochondrial 
oxygen consumption in the C2C12 myotubes. This result suggests that Rap1 is 
important in mitochondrial function, and hints again at the many effects statins can 
have in a cell.  
Mitochondrial function and integrity is reliant upon multiple signalling pathways, one 
of which is the Igf-1/Akt pathway.115,149–151  To test whether this pathway protects the 
HepG2 cells from statin-induced toxicity, we co-incubated these cells with an Akt 
inhibitor. Neither the Akt inhibitor nor simvastatin alone were toxic to the HepG2 cells, 
but co-incubation led to increased cell death, and also a decrease in mitochondrial 
oxygen consumption. This demonstrates both the importance of Igf-1/Akt signalling in 
maintaining correct mitochondrial function and also in protecting from simvastatin-
induced toxicity. 
To conclude, this part of the thesis has fully characterized the differing responses to 
simvastatin in skeletal muscle C2C12 myotubes and liver HepG2 cells. These differences 
in cholesterol metabolism, mitochondrial function and Igf-1/Akt signalling offer clues as 
to why statins can lead to toxicity in skeletal muscle and not in liver.  
7.3.  Cardiomyocytes are also susceptible to simvastatin-induced  
       toxicity 
The second part of the thesis investigated the effects of simvastatin-treatment on cardiac 
tissue and cells. This work is of vital importance as the majority of statins are prescribed 
to prevent cardiovascular diseases. Something that could have an adverse effect on the 
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very organ it is trying to protect could be disastrous, especially as cardiac side-effects 
could be masked by falsely attributing them to the underlying disease. 
We observed a reduction in heart weight in Wistar rats treated with simvastatin, and 
used in vivo and ex vivo models for further investigation. Simvastatin-toxicity in H9C2 
cardiomyocytes was seen at both a mitochondrial and atrophic level. Similar to the 
C2C12 myotubes, mitochondrial oxygen consumption was reduced and atrogin-1 
expression increased in the treated cardiomyocytes. A major observation was that the 
reduction in oxygen consumption occurred after only 6 h treatment with 10 µM 
simvastatin (a timepoint at which we saw no cytotoxicity). This suggests that changes in 
the mitochondria are a cause, rather than a consequence, of simvastatin-induced toxicity 
in H9C2 cardiomyocytes. This complements work in other cell lines, and is the first time 
a direct effect on oxygen consumption in mitochondria has been seen in a cardiac cell 
line.118,120,122  The reduction in mitochondrial respiration was confirmed in isolated 
neonatal rat cardiomyocytes. The cardiomyocytes also showed a reduction in glycolysis. 
It is tempting to link these reductions in oxygen consumption and glycolysis to a 
disruption in Igf-1/Akt signalling. An inhibition in Igf-1/Akt signalling is indirectly 
pointed to by our results showing an increase in Foxo3a translocation to the nucleus 
and atrogin-1 transcription. 
Although preliminary, our data show for the first time that simvastatin could adversely 
alter mitochondrial function and induce signs of atrophy in cardiomyocytes. The exact 
toxic mechanisms remain to be uncovered, so further work is required to expand on 
these results and fully determine any detrimental effects of statins on cardiac tissue. 
This will be particularly important if similar statin-induced cardiotoxicity is found in 
human subjects. With demographic changes resulting in an aging population in 
Western countries, it can be expected that statin use will further increase in the future. It 
is therefore of great importance to ensure that these drugs are used safely. 
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7.4.  Important points 
In summary, we provide important differences in the response to simvastatin between 
C2C12 myotubes and HepG2 cells. These differences centre on the response of the Igf-
1/Akt signalling pathway, and open up new areas of research into the exact mechanism 
of statin-induced toxicity – particularly involving the importance of the small GTPase, 
Rap1. In addition, we have become the first group to uncover adverse effects of 
simvastatin on cardiac muscle. As with skeletal muscle, we show inhibition of 
mitochondrial respiration and upregulation of atrogin-1 synthesis. Overall, this thesis 
contributes to our knowledge of how simvastatin causes toxicity, provides novel 
mechanisms for linking mitochondrial toxicity to cell signalling, and opens up a new 
area of research into toxic effects in cardiac muscle 
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